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Abstract
Radiation therapy is an important component of pediatric brain tumor treatment.
However, radiation-induced damage can lead to adverse long-term health effects.
Proton therapy has the ability to reduce the dose delivered to healthy tissue when
compared to photon radiation therapy, but this dose benefit comes at a significantly
higher initial cost, as proton therapy is 2 to 3 times more expensive to deliver than
photon therapy.
This thesis provides a framework for the evaluation of health and cost effective-
ness of proton therapy compared to Intensity Modulated Radiation Therapy (IMRT).
Proton therapy and IMRT treatment plans of patients treated for low-grade gliomas
(LGGs) were analyzed to provide risk estimates of long-term health effects based on
the dose distributions. A Markov simulation model was developed to estimate the
health effects and costs of proton therapy and IMRT. The model tracked a pediatric
cohort treated for LGGs at age 5. In the model, the patients were at risk of acquir-
ing IQ loss, growth hormone deficiency (GHD), hypothyroidism, hearing loss, and
secondary cancer. Patients faced risks of death due to tumor recurrence, secondary
cancer, and normal death. In addition, a review of literature was performed to esti-
mate the costs and additional health risks not determined from the patient treatment
plans.
The simulation results show that proton therapy can be cost effective in the treat-
ment of LGGs based on the health risks estimated from the patients treatment plans.
The cost associated with IQ loss and GHD were the main contributors to the total
costs from long-term health effects. Proton therapy also results in a lower level of IQ
loss and a lower risk of acquiring other long-term health effects. However, the relative
difference in IQ point loss between the treatment modalities is small in the limited
number of patients studied. There is a need to further investigate the advantages of
proton therapy in reducing the dose delivered to the relevant parts of the brain to
lower the risks of adverse health effects, especially for IQ loss.
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Title: Senior Research Scientist
Thesis Supervisor: Jacquelyn C. Yanch
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Chapter 1
Introduction
Cancer is a leading cause of morbidity and mortality in the United States, accounting
for nearly 1 in every 4 deaths. [1] In 2008, the cost of health expenditures for cancer
care was $93.2 billion, accounting for roughly a third of the total health expenditure
in the U.S. of $2.93 trillion [1] [2]. Radiation therapy is an important aspect of cancer
treatment, used for approximately half of all cancer cases and often in conjunction
with chemotherapy and surgery [3] [4]. Innovations in radiation therapy have led to
more advanced radiation technologies, resulting in increased survival and improved
quality of life for patients [5]. Proton radiotherapy and IMRT improve radiation
therapy by targeting the dose to the tumor and minimizing the dose delivered to
healthy tissue.
The support for proton therapy is based on the improvement in dose distribution
that protons can provide [6]. Since radiation to healthy tissue is correlated with
adverse health effects, treatment plans always aim to reduce radiation dose outside
of the tumor volume. Due to their physical properties, protons are theoretically
better able to target the tumor while significantly sparing healthy tissue compared
to photons used in conventional radiation treatment.
The most advanced form of photon therapy is Intensity Modulated Radiation
Therapy (IMRT). IMRT changes the fluence of the beams to target the tumor and
spare the surrounding healthy tissue. [7] IMRT provides a high degree of control over
the dose distribution to tumor and healthy tissue by modulating the intensity of the
photon beams, using cutting-edge optimization algorithms and multileaf collimators
systems (MLCs) to shield and reduce the dose delivered to the tissue around the
tumor.
Studies have shown that proton therapy spares more healthy tissue than IMRT
during treatment. [8] [9] [10] However, proton therapy is more expensive than IMRT
(estimates range from 30-500% more expensive), and questions remain regarding
whether this cost is justified in terms of both short and long-term health improve-
ments. [11] [12] Some state that proton therapy is projected to remain always more
expensive than photon therapy, even with improvements in technology and learn-
ing. [12] Systematic reviews of the effectiveness of proton therapy in clinical practice
point to the need for more research into the clinical and cost effectiveness of proton
therapy. [13] [14] [15] After 30 years of proton therapy use, there appears to be no
extensive randomized clinical evidence that protons provide better health outcomes
than photons, except for ocular, brain, and pediatric tumors. [16] Even within the
tumor types for which proton therapy is more effective, additional studies are needed
to quantify the extent of the health and cost benefits.
This thesis addresses the need for evaluating the long-term health and cost effec-
tiveness of proton therapy. The goals of this thesis are three-fold:
1. To provide a framework to estimate the long-term health effects and costs of
proton therapy compared to IMRT.
2. To test if proton therapy reduces long-term health effects when compared to
IMRT by analyzing patient treatment plans and modeling.
3. To determine whether the difference in risk of long-term health effects, calcu-
lated from the patient treatment plans dose-volume data, leads to an overall
reduction in costs for proton therapy.
Since proton therapy is significantly more expensive than IMRT, questions remain
regarding whether this cost is justified in pursuit of both short-term and long-term
health improvements. The thesis addresses the following research questions:
1. Based on the difference in dose distribution between proton therapy and IMRT
treatment plans, to what extent is proton therapy able to reduce the risk of
adverse health effects?
2. Using the framework developed in this thesis, is proton therapy more cost-
effective than IMRT for the treatment of pediatric low-grade gliomas when
long-term morbidities are considered?
To limit the scope of this thesis, the assessment will be focused on the use of pro-
ton therapy for the treatment of pediatric brain tumors. Radiation therapy irradiates
healthy brain tissue, and it is imperative to limit the dose delivered to the healthy
brain to lower the risks of adverse health effects. Children are a particularly difficult
population to treat as they are more sensitive to radiation and more likely to expe-
rience adverse health effects. [17] [18] The treatment of pediatric brain tumors using
radiation can lead to severe health effects such as endocrine abnormalities, hindrance
of growth, and impaired neuropsychological development. [17] [19] Since pediatric pa-
tients are likely to become long-term cancer survivors, post-treatment complications
may be chronic and costly. As a positive correlation exists between adverse health ef-
fects and dose/volume delivered to healthy tissue, pediatric patients could potentially
benefit from the improved dose distribution offered by proton therapy. [19] [20]
The target audience for this thesis is the four main stakeholders in the treatment
of pediatric brain tumors using radiation therapy: patients, physicians, payers, and
politicians. Patients are interested in receiving the best treatment available and will
want to know what benefits in health effects can be expected from proton therapy.
Payers (i.e. insurance, Medicaid, or out-of-pocket) and politicians will be interested in
the cost-effectiveness analysis to determine whether proton therapy is a worthwhile in-
vestment. This thesis provides a framework for comparing proton therapy and IMRT
to aid the stakeholders in deciding which treatment method is most appropriate.
Chapter 2 provides background information on the history and physics of pro-
ton therapy and IMRT. Chapter 3 provides a review of literature on the risk of the
long-term health effects after radiation treatment for low-grade gliomas (LGGs). The
chapter focuses on IQ loss, growth hormone deficiency (GHD), hearing loss, hypothy-
roidism, and secondary cancer. Chapter 4 covers the methodology of the evaluation,
detailing how the Markov model simulating two groups of patients treated with pro-
ton therapy and IMRT respectively was designed and how the risks and costs of each
long-term health effect were determined . Chapter 4 also explains how the patient
treatment plans were analyzed. Chapter 5 describes the estimated health effects
from the treatment plan analysis and results of the model simulations based on the
health parameters of each patient. Chapter 6 summarizes the results, pointing out
the limitations of this framework and proposing areas for future work.
Chapter 2
Radiation Therapy Background
This chapter provides an overview of radiation therapy. A short history of radiation
therapy is covered, with a focus on the development of proton therapy and IMRT.
Section 2.2 discusses the differences between the two treatment modalities. Finally,
a review of the physics and biology of radiation therapy is included.
2.1 History of Proton Beam Therapy and Inten-
sity Modulated Radiation Therapy
Radiation therapy is a form of cancer treatment that uses radiation to destroy malig-
nant cells, and proton beam therapy is a form of radiation therapy that uses protons.
Physics research has led, directly and indirectly, to many advances in radiation ther-
apy. With the discovery of x-rays in 1895 by Wilhelm Conrad Roentgen (who went on
to win the Nobel Prize for his discovery), it was a matter of months before radiation
began to be used as a cancer treatment. [21] In 1919, another Nobel Prize winner,
Ernest Rutherford, showed the existence of protons by bombarding light elements
with alpha particles, generating fast protons in the process. [22] This discovery, cou-
pled with Ernest 0. Lawrence's (also a Nobel prize winner) invention of the cyclotron
- a machine able to accelerate charged particles to very high energies - in 1931, cre-
ated the basis for proton beam therapy. [23] The theory of proton beam therapy was
developed in 1946 when physicist Robert Wilson published a study suggesting the
potential benefits of protons in delivering a higher dose of radiation to the tumor
while reducing the dose to the surrounding healthy tissue. Advances in imaging tech-
nologies in the 1980s allowed proton therapy (which requires precise location of the
tumor) to become a viable treatment option.
The mid-20th century proved to be a productive time for cancer treatment, es-
pecially for radiation therapy. A particularly pivotal year was 1937, when cancer
caught the American public's interest, with Fortune, Life, and The New York Times
publishing articles and reports calling for a great need for action against cancer. [24]
The U.S. Congress promptly passed the National Cancer Institute (NCI) Act on July
23, 1937, creating a new body to organize cancer research and education in the U.S.
The first hospital-based clinical use of photon therapy was performed at University
of California Berkeley (UC Berkeley) on a patient with leukemia. [23] UC Berkeley
would also be the first to conduct animal and human proton therapy experiments in
1948 and 1954 respectively. After UC Berkeley's human trial in 1954, other institu-
tions began to treat patients using proton therapy, including Harvard University led
by a group from the Massachusetts General Hospital (MGH). [5]
Today, most radiation treatment occurs using high-energy x-ray beam (often re-
ferred to as photon beam), where photons are generated external to the patient and
focused in a beam to target the tumor. [21] Intensity Modulated Radiation Therapy
(IMRT) is the favored radiation treatment method using photons - according to a sur-
vey in 2004, 73% of responding U.S. radiation oncologists said they use IMRT. [25]
As its name suggests, IMRT modulates the intensity of the radiation beams during
treatment. These changes in the beam intensity create a treatment that manages "a
higher degree of spatial agreement ('conformality') of the resulting dose distribution
with the tumor target volume." In other words, the intensity of the photon beam is
designed to be higher for the tumor volume and lower for the surrounding healthy
tissue.
IMRT was first proposed in 1982 in a paper published by Anders Brahme et al,
showing how to calculate a plan of non-uniform beams based on the desired dose
prescription - a process known as "inverse planning." [26] [21] Independently, Alan
Cormack also proposed the idea that year, right after co-inventing the computed
tomography (CT) scanner. The invention of the CT scanner played an important
part in the development of IMRT, as advanced imaging techniques were necessary to
detect the complex geometry of the tumor volumes and surrounding tissues.
Proton therapy, despite its late entry as a radiation-based treatment, is increasing
the number of systems as demand quickly rises. As of 2008, nearly 20,000 patients
have been treated with proton therapy in the U.S. and over 40,000 people treated
worldwide. [27] [28] The number of proton therapy centers has quickly been growing.
In the U.S., the first proton center was opened in 1991 at Loma Linda University
Medical Center in California, followed a decade later by a flurry of proton center
construction, starting with the Francis H. Burr Proton Therapy Center at MGH. [23]
Currently, there are 29 proton centers operating around the world, and more are
being built. [29] Proton therapy is used to treat a wide variety of tumors, including
head and neck, pediatric tumors, ocular, lung, gastrointestinal, gynecological, bone
and soft tissue, lymphoma, breast, and prostate tumors. [30] [31]
2.2 Proton Therapy Compared to IMRT
Radiation as a treatment tool is a double-edged sword: it effectively kills tumor cells
but also damages healthy cells in the process. Since radiation to healthy tissue is
correlated with adverse health effects, treatment plans always aim to improve tumor
target and reduce radiation outside of the tumor volume. [32]
Proton therapy holds the promise of being a more effective radiation therapy
than IMRT. Protons have the inherent physical properties of depositing most of their
energy after traveling a well-defined distance. Protons can only travel a finite distance
and deliver most of their energy at the end of their range - a phenomenon known as
the Bragg peak (Figure 2-1).
Photon interactions occur based on a probability of interaction per distance, which
depends on the target medium and photon energy. As photons travel through mat-
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Figure 2-1: The Bragg peak, showing the finite range and location of peak energy
deposition of protons in water. [21]
ter, they deliver the maximum dose near the beginning of their path and gradually
attenuates. This attenuation gradually reduces the dose delivered as the number of
photon decreases, as shown in Figure 2-2.
Since photons only gradually attenuates, they continue to deliver a dose beyond
the tumor target, which is know as the exit dose. Protons are able to eliminate this
exit dose as they have a sharp drop-off in their energy deposition at the end of their
range. As shown in Figure 2-3, protons are able to deliver most of their energy within
the target area (between the dashed green lines) and stop shortly after; photons,
however, continue to deliver a dose beyond the tumor target. As the Bragg peak
occurs at a narrow point, it is necessary in clinical practice to superimpose multiple
Bragg peaks to give the appropriate dose to the target volume. This addition of
multiple Bragg peaks creates a spread-out Bragg peak (SOBP), as shown in Figure
2-3.
A number of studies have been published comparing the dose-volume distribution
of proton therapy and IMRT for solid pediatric brain tumors. [8] [9] [20] All the studies
show that proton therapy spares more healthy tissue than IMRT and conventional
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Figure 2-2: Attenuation of a 6 MeV photon through a water phantom, both simulated
(Monte Carlo) and measured. [33]
photon therapy. A study published by St. Clair et al showed significant differences
between proton therapy and photon treatment plans. In the case of medulloblastoma,
a tumor in the posterior fossa, proton therapy is able to conform to the relevant
body part and avoid irradiating other volumes. Medulloblastoma treatment requires
irradiation of the entire spinal cord, which results in irradiation of the chest area when
using photons. Figure 2-4 shows an image of the percent of full dose delivered to the
spinal cord and chest, with proton therapy significantly sparing the chest, avoiding
dose to critical organs.
Proton therapy is most promising in reducing the risks of adverse health effects for
the treatment of pediatric tumors. Children diagnosed with cancers today have over
an 80% chance of 5-yr survival. [34] [35] [36] Cancer survivors may suffer from a range
of adverse health effects associated with the treatment of the primary tumor. [32]
The need to reduce the dose delivered to normal tissue is especially imperative when
treating children who are more sensitive to radiation and who live longer with adverse
health effects than adults. [10] [37] A few studies have indicated that the differences
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Figure 2-3: Comparison of the dose deposition between protons and photons in tissue.
The black line represents a 15 MeV photon beam, the blue lines repesent multiple
Bragg peaks that make up the spread-out Bragg peak (red line). The dashed green
line delineates the tumor target. [21]
in dose distribution between proton therapy and IMRT can result in a lower incidence
of common pediatric late health effects. [20] [38] [39] Even though proton therapy has
demonstrated its potential in reducing the radiation dose delivered to healthy tissue,
there is still a dearth of data on clinical evidence indicating health benefits from
proton therapy compared to IMRT. [14] [15] In part, this is because proton therapy
there ha been a lack of randomized clinical, and those studies are slowly starting to
appear. Another reason is that it is difficult to have long-term comprehensive follow-
ups with patients who come from all over the country to be treated and do not return
afterwards. [40]
It is also not always the case that proton therapy results in a clinically significant
improved dose distribution compared to IMRT. Looking at Figure ??, proton therapy
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Figure 2-4: Dose distribution along the spinal column of a child treated with coven-
tional X-rays (top left), IMRT (bottom left), and protons (bottom right). Significantly
lower doses are delilivered to the torso when treating with proton therapy compared
to conventional x-rays and IMRT. [8]
is a clear improvement over conventional photon therapy treatment, but the difference
between IMRT and proton therapy is not as pronounced. Follow-up studies of patients
who have been treated with proton therapy seem to indicate that protons do lead to
a lower risk of side effects in certain situations - but not all. For example, a recent
study by Winkfield et al found that the risk of getting a secondary cancer from proton
therapy can be higher than from IMRT depending on the number of fields used. To
reduce the total dose that each beam delivers to a particular area, the number of
beams used is increased; however, this results in more healthy tissue being irradiated,
which could explain the increased secondary cancer incidence.
In the face of the paucity of randomized clinical data, this thesis aims to evaluate
the extent to which differences in health effects can be expected based on the dose
distribution from actual proton therapy and IMRT treatment plans. Models have
been developed to quantify the dose-volume effects of radiation on risk of adverse
health events from the follow up of patients treated with photon radiation. Merchant
et al developed models that relate dose to magnitude of IQ loss and GHD. [41] [42] [43]
The risk of hearing loss was found to increase based on the mean dose delivered to
the cochlea. [44] Furthermore, each one of these morbidites have a cost associated to
it. This thesis provides a model to determine whether proton therapy is effective in
reducing the incidence of health effects and their associated costs.
2.3 Radiation Physics and Biology of Radiation
Therapy
The information in this section is primarily drawn from the books by Turner and
Goitein, unless otherwise noted. [45] [21]
2.3.1 Photons
Photons are light particles and have neither electric charge nor actual mass. They
can be referred to as gamma rays or x-rays, based on their origin. Gamma rays come
from atoms with an excited nuclear state, causing the nucleus to release its excess
energy in the form of photons to reach a stable state in a process known as gamma
decay. As Roentgen discovered in his cathode ray experiment, x-rays are generated
when electrons are sent towards a heavy target (i.e. target made of atoms with
a high atomic number). Those electrons collide with other electrons in the target
or be deflected from their course as they pass near the positively charged nuclei,
losing energy by releasing an x-ray photon. This creation of a photon by particle
deceleration is known as bremsstrahlung, which comes from the German words for
'to brake' (bremsen) and 'radiation' (Strahlung). [46] In this thesis, x-rays will be
referred to as photons unless otherwise specified.
2.3.2 Protons and the Bragg Peak
Protons are positively charged particles that interact with matter via two main types
of interactions: Coulombic interactions (with atomic nucleus and electrons) and nu-
clear interactions with the atomic nucleus. As a proton traverses a medium, it can
attract electrons away from atoms, ionizing the atom and setting electrons loose.
Protons do not lose much energy during a Coulombic interaction with electrons and
will experience, on average, hundreds of thousands such interactions per centimer tra-
versed. Since protons are 1836 times heavier than electrons, they barely experience
any deflection from their path. However, protons will experience a repulsive force
when passing near the atomic nucleus, which is positively charged. Since the atomic
nucleus is usually heavier than a single proton, the nucleus will deflect the proton
(albeit, at a small angle).
The Bragg Peak is a result of proton's Coulombic and nuclear interactions. Pro-
tons slowly lose their energy through thousands of Coulombic interactions with elec-
trons, but this energy loss varies as protons travel through matter. Like all heavy
charged particles, protons lose their energy as defined by the Bethe-Bloch stopping-
power formula. As protons slow down, tehy transfer more energy during each collision,
resulting in a peak rate of energy loss near the end of their trajectory, as indicated in
Figure 2-1.
2.3.3 DNA Damage
Radiation damages a cell by breaking bonds in DNA, effectively killing the cell or
stopping the cell's ability to reproduce. As radiation travels through the body, it
interacts by ionizing the particles in the cell - particularly water molecules (-70-85%
of the makeup of human cells). Radiation can affect a cell's biology directly and
indirectly. For example, a direct effect can result from the radiation ionizing atoms
in the DNA helix, breaking the DNA bonds. Radiation can generate indirect effects
by forming free radicals (i.e. particles with unpaired electrons, such as H20+ and H)
or other byproducts. These byproducts can subsequently interact with DNA, such as
a free radical reacting with DNA sugars and resulting in a stand break.
Tumor and healthy cells respond differently to radiation interactions. Tumor cells
tend to be more susceptible to radiation damage, likely due to their genetic makeup -
though this phenomenon is currently not completely understood. This phenomenon
is especially useful when healthy cells are found within the tumor or nearby but are
included in the target volume.
2.3.4 Radiation Dose
Dose delivered to a patient is measured in terms of Gray (Gy). A Gray represents
the energy from radiation absorbed per unit mass, where:
1 Gy= 1 J/kg
Radiation therapy can deliver doses up to 60 Gy to certain parts of the body. An
acute delivery of the full dose (on average around 50 Gy, though greatly depends on
tumor) required to destroy a tumor could kill the patient if delivered acutely to the
whole body or critical organs. Hence, fractionation is an extremely important aspect
of radiation treatment. A treatment plan will conventionally be broken up into 2 Gy
fractions delivered once a day, with a break over the weekend.
2.3.5 Relative Biological Effectiveness
The effectiveness of different types of radiation is compared using their relative bi-
ological effectiveness (RBE). RBE is defined as ratio of the x-ray dose compared to
dose of another radiation type required to produce the same specific biological end
point (e.g. level of tumor cell deaths). RBE is determined by:
RBE = Dx-rayD
where D is the dose of a type of radiation that produces a particular biological end
point and Dx-ray is the x-ray dose needed to reproduce that end point.
Protons are generally accepted of as having an average RBE of 1.1, meaning that
it would require about 10% more x-ray dose to reach the same biological end point
as protons.
Based on the physical properties of protons, proton therapy can significantly re-
duce the dose delivered to healthy tissue. This benefit is especially important when
treating pediatric patients who are not fully developed and are more sensitive to radi-
ation damage. The next chapter discusses the health risks associated with childhood
brain tumor survival, with a focus on the effect of radiation on those risks.
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Chapter 3
Pediatric Low-Grade Gliomas and
Long-Term Health Effects
Gliomas are tumors of the central nervous system (CNS), which consists of the brain
and spinal cord. CNS tumors are the second most common tumors in children after
hematological malignancies. [47] Every year, about 43,800 cases of brain tumors are
newly diagnosed in the U.S. Roughly 3,000-4,000 of those cases are pediatric brain
tumors. Low-grade gliomas (LGGs) are the most common form of pediatric brain
tumors, accounting for roughly 50% of all cases. [48] LGGs are generally slow growing
and benign tumors, thus increasing the chance of survival. LGGs are usually treated
with surgery (resection of some or all of the tumor volume), chemotherapy, radiation
therapy, or a combination of the three. [49] [50] Most LGG patients will require
radiation therapy, especially for centrally located tumors that cannot be removed by
surgery. [42]
The advantages of more precise radiation therapy are especially important for
pediatric LGG survivors. Children treated for LGG are most likely to survive com-
pared to the population treated for all brain tumors, with 10-20 year survival rates
well above 80%. [48] [51] [52] Since many children with LGG will become long-term
survivors, they are likely to experience a number of adverse health effects after treat-
ment. Children who survive brain tumors are especially susceptible to long-term
morbidities as children's brains are not fully developed by the time of disease onset
and treatment. [47] The main health effects of concern from radiation treatment are
neurocognitive, endocrine, and ototoxicity disorders, and secondary cancer. [52] [42]
3.1 Neurocognitive Dysfunction
Partial to full irradiation of the brain can result in multiple, long-term neurocognitive
effects such as attention, memory, language, and executive function deficits. [53] [54]
Intelligence Quotient (IQ) has been used as a benchmark to quantify the extent of
neurocognitive damage. IQ is a score generated from tests designed to assess intelli-
gence. Pediatric patients who receive radiation treatment are likely to experience IQ
loss, with IQ changes greater than 10%. [41] [55] The relationship between radiation
dose to the brain and IQ loss is not fully understood, though it is generally accepted
that a higher dose to the brain will result in a higher level of IQ loss. [50]
Fuss et al performed a systemic review of 36 publications on neuropsychological
impairments from children treated with radiation. [56] The data from the publications
represents 1,938 children and examines radiation dose, irradiated volume, and age.
Doses greater than 24 Gy resulted in IQ loss. Age was a clear factor in IQ score,
with children under the age of 3 receiving doses higher than 24 Gy having lower than
normal IQ scores (less than 85 points); while children older than 6 experienced that
level of IQ deficiency when receiving doses higher than 36 Gy.
Researchers at St. Jude Children's Research Hospital have published various
studies that investigated the dose-volume effect of radiation on the magnitude of IQ
loss. [41] [51] Merchant et al found mathematical relationships between dose to brain
and IQ loss from studies of pediatric patients with LGGs. The group developed
different IQ loss models for specific brain tumors: all LGGs, craniopharyngomas
(CR), ependymomas, and medulloblastomas (MB). Merchant et al chose those specific
tumors due to their different locations in the brain: ependymomas and MBs can be
found in the infratentorial region; LGGs and CRs can be found in the supratentorial
region, closer to critical structures such as the left temporal lobe, puitary glands and
hypothalamus. [20]
For all LGGs, the study analyzed a group of 78 pediatric patients treated with
54 Gy of CRT between August 1997 and August 2006. [42] Merchant et al found
that a patient's IQ loss was dependent on the dose-volume distribution given to the
supratentorial brain (the top area of the brain, consisting of all brain except for the
posterior fossa) and age at radiation treatment, as shown in Equation 3.1:
IQ = 95.5545+Age x 0.3291 +Time x (Age x 0.00273- Vo-o x 0.0027- V3 0 -6o x 0.0047)
(3.1)
where Age is the age in years when patient receive radiation treatment, Time is the
time in months since radiation treatment, V- 30 is the percentage of supratentorial
brain that received 0 to 30 Gy, and V30-6 0 is the percentage of supratentorial brain
that received 30 to 60 Gy. The more volume of the supratentorial brain that received
a high dose (30-60 Gy) resulted in a higher overall IQ loss. Age at time of treatment
was also a factor that influenced the magnitude of IQ loss (i.e. worse for younger
patient).
For ependymomas, the study followed 88 patients who received 54-59.4 Gy during
radiation treatment from July 1997 to January 2003. The group found an estimation
equation for the dose to the supratentorial brain. [41] The MB and CR models were
less detailed, only using the mean dose to the supratentorial brain to estimate IQ. [20]
The analysis of Merchant et al's studies led to two points of confusion. The first
is that the standard errors to the IQ loss are poorly defined (if at all). Specifically,
it is not clear if all patients should expect IQ loss based on his mathematical models
or not. Second, his study for IQ loss after CRT for enpendymoma provides multiple
mathematical models, correlating IQ loss with dose to the whole brain, left temperoral
lobe, and supratentorial lobe individually. Testing of those equations with data from
the treatment plan used in this thesis of a patient with an ependymoma provide
different values for IQ loss depending on the brain structure.
Ultimately, it is unclear if dose to the supratentorial brain is solely responsible for
IQ loss as other studies show IQ loss related to dose to other parts of the brain. Jalali
et al found a significant difference in the risk of obtaining a high IQ loss (greater than
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Figure 3-1: IQ loss comparison based on dose to the supratentorial brain. Significant
difference in IQ loss can be expected for patients treated with a higher dose to the
supratentorial brain. This graph was generated using the dose-IQ relation developed
by Merchant et al. [51]
10 points) if at least 13% of the left temporal lobe received 43.2 Gy or higher. Other
studies have analyzed the loss of normal white matter and found a correlation with
neurocognitive defects. [52] [54] Nevertheless, the Merchant et al studies are currently
the only studies that mathematically model IQ loss based on dose to the brain. As
proton therapy has the ability to deliver less high doses to the supratentorial brain
during treatment, it would be expected that significant differences in IQ loss would
be found between proton therapy and IMRT.
3.2 Endocrine Dysfunction
Endocrine complications occur from damage to the hypothalamus and pituitary gland,
which disrupts regular hormone release. Two common endocrine complications of
brain tumor survivors are growth hormone deficiency (GHD) and hypothyroidism.
GHD is usually caused by the loss of the growth hormone-releasing hormone neu-
rons in the hypothalamus. [43] The reports of GHD incidence varies from study to
study, based on the tumor type and the number of patients available for analysis.
Incidence of endocrine dysfunctions will be as high as 83% for a pediatric LGG pop-
ulation, with the majority from GHD. [52] A study from St.Jude Children's Research
Hospital (n= 78) found a 10-year cumulative rate of GHD at 49% for LGG pediatric
patients treated with photons. [51]
Growth hormone therapy is usually stopped once children reach their final height. [57]
However, it does not necessarily mean that the patient is no longer growth hormone
deficient. Gleeson et al tested a group of 73 children about 10 years after radiation
therapy, at an average age of 15 years, which is usually when growth hormone treat-
ment is stopped. [58] All the children were on growth hormone replacement for severe
or moderate GHD. The study found that ~50% of the pediatric cohort with GHD
after radiation treatment tested positive again for GHD at final height. A similar
study by Gurney et al found that close to 40% of the childhood brain cancer sur-
vivors were below the 10th percentile for height. The Gurney et al study was part
of the Childhood Cancer Survivor Study and was able to draw data from 921 young
adult survivors of brain cancer.
Hypothyroidism is a condition in which the thyroid does not produce a suffi-
cient level of hormones. [59] Thyroid hormones are crucial in regulating the body's
metabolism, temperature, heart rate, protein production, and calcium in the blood.
The hypothalamus and pituitary glands control the rate at which thyroid hormones
are released, and hence any damage caused by radiation can result in disruption in
the thyroid hormone release. The same LGG study from St.Jude Children's Re-
search Hospital found a 10-year cumulative incidence of hypothyroidism at 68%. [51]
Their findings were aligned with the findings by Rose et al reporting 69% of patients
with brain or nasopharyngeal tumors with hypothyroidism. [60] No studies so far
have attempted to model the correlation between dose and level of thyroid hormone
deficiency.
Other endocrine dysfunctions, such as diabetes, delayed or early onset of puberty,
and testosterone deficiency, were not explored in this study. These deficiencies have
been noted but have not been studied as completely; therefore, the risks of those
health-effects were not considered in this thesis.
3.3 Hearing Loss
Hearing loss is a common side effect in patients treated with radiation for brain, head,
and neck tumors. [44] [61] The onset of hearing loss usually occurs when the cochlea
receives high doses of radiation, in excess of 30 Gy. [42] The area that translates
high frequencies (4000-8000 Hz) is more sensitive to radiation than other parts in the
cochlea. High frequencies are crucial in the understanding of speech, with 50% of
English sounds at energy frequencies up to 8000 Hz. [61]
The threshold for hearing loss for children is between 35-45 Gy. [44] [62] Chiaho
Hua et al reported a hearing loss rate of 14% from a study of 78 patients with localized
brain tumors followed 3-5 years after radiation treatment. [44] Hearing loss incidence
increased for doses greater than 40Gy, with a higher risk of loss at higher frequencies
(6000-8000 Hz). The study found that the onset of hearing loss occurred 3-5 years
post treatment for 75% of the cases, though hearing loss can occur as early as 2 years
after treatment. Median hearing loss onset is 3.5 years post treatment.
A group at Texas Children's Hospital investigated the onset of hearing loss in 44
pediatric patients treated for medulloblastoma from 1998 to 2006 using IMRT. [62]
The median follow-up time was 41 months. They found that 25% of the children
experienced high frequency hearing loss, with the higher mean dose to the cochlea
increasing the severity of the hearing loss.
Merchant et al's follow-up of 78 pediatric patients with LGG found that doses
greater than 45 Gy resulted in significantly higher risk of high frequency hearing
loss. For 6000 and 8000 Hz frequencies, the risk of hearing loss at doses greater
than 45 Gy was 19.2% each compared to 0% at less than 45Gy. The group only
found a correlation between dose to the cochlea and hearing loss in the right ear.
There are multiple other factors that could be associated with hearing loss, such as
genetic make-up and chemotherapy; however dose to the cochlea still remains the
main factor. [44]
3.4 Secondary Cancer
Currently in the United States, about 10% of cancer patients are treated for a sec-
ondary malignancy. [37] Secondary cancer is the onset of another malignancy after
the treatment of the primary tumor. The risk of secondary cancer is associated with
genetic make-up, type of primary tumor, and treatment method. [39] [63] Children
are especially susceptible to secondary cancers for three reasons: [37]
1. They are 10 times more sensitive to radiation than adults. Studies of the
Japanese atomic-bomb survivors show an increased risk of radiation-induced
cancer at a younger age.
2. Any radiation scatter is more likely to deliver a higher dose to critical organs
than for adults, as shown in Figure 3-2.
3. Children with primary cancers are likely to have genetic mutations that make
them more prone to radiation-induced cancers. For example, children treated
with radiation for Hodgins disease were had a higher risk of breast cancer than
children treated for other tumors. [?] However, the general understanding of
genetic susceptibility is still unclear and requires further study.
The most extensive secondary cancer study has been the Childhood Cancer Sur-
vivor Study (CCSS). [64] [65] CCSS is a large retrospective study of over 14,000
childhood cancer survivors. The follow-up period of the patients is the longest to
date: 25-30 years after treatment of the primary tumor. The patients included in
the study survived for at least 5 years after treatment. The study analyzed the inci-
dences of secondary cancer based on many different criteria, such as gender, age at
diagnosis, primary tumor diagnosis, and primary tumor treatment. The cumulative
30-year incidence of secondary cancer was 9.3%. [64] Female survivors were 1.64 times
more likely to develop a secondary cancer than male survivors. Radiation therapy
increased the risk of secondary cancer, especially if the patient was treated for the
Figure 3-2: Comparison of scattered dose to body when treating an adult (left) and
a small child (right).[37] A more significant volume of the child's body is irradiated
compared to the adult's irradiated volume for the treatment of a similar tumor vol-
ume.
primary tumor at a younger age. A more focused analysis of the CCSS found that
patients treated with radiation therapy were more likely to develop a secondary CNS
cancer. [65]
Researchers at St. Jude Children's Research Hospital performed a study on a
cohort of 1,283 patients treated for pediatric CNS tumors between January 1984 and
January 2002. [66] The patients were all under 22 years at time of treatment. The
study found that the 14-year cumulative incidence of secondary cancer was 5.3%
(95% CI, 2.0-8.5%). The 10-yr estimated cumulative incidence of second malignant
neoplasms for patients with LGGs was 0.4% (95% CI, 0-0.8%). All the patients with
a secondary cancer from LGGs (n=10) were treated with radiation therapy for the
primary tumor and received on average 50 Gy at the site where the second tumor
appeared. However, the study was unable to parse out the effect of chemotherapy
and radiation therapy on the risk of secondary cancer.
Recent studies have modeled the risks of secondary cancer from proton ther-
apy and IMRT. Mu et al compared treatment plans for medulloblastoma based on
IMRT, intensity modulated proton therapy (IMPT), conventional electron therapy,
and intensity-modulated electron therapy (IMET).?? IMPT differs from proton ther-
apy in that it utilizes magnetically scanned pencil beams that specifically conform
to the target volume. [7] Conventional proton therapy uses broad proton beams that
are molded to the patient by using specially designed apertures and compensators for
each patient - a process known as passive scattering. The group found that IMRT
had the highest risk of secondary cancer (30%) and IMPT had the lowest risk (4%).
However, IMPT is not currently the main form of proton therapy treatment as most
facilities use the passive scattering technique. It is expected that the risk of secondary
cancer from proton therapy is higher than the risk from IMPT.
Miralbell et al and Winkfield et al also analyzed the risk of secondary cancer
from proton therapy. [39] [67] The Miralbell et al study designed treatment plan for
two cases of pediatric brain tumors: parameningeal rhabdomynsarcoma (RMS) and
MB. [39] Using the dose-volume histograms generated from the treatment plans, they
estimated a yearly risk of secondary cancer risk for IMRT and proton therapy at
0.43% and 0.05% respectively for MB. The yearly risk for RMS was 0.05% for IMRT
and 0.04% for proton therapy. The risk of secondary cancer from MB treatment is
expected to be higher than for RMS treatment as the whole brain and spinal cord
are irradiated. Only the tumor volume is targeted in radiation treatment of RMS.
The Winkfield et al study estimated the risk of secondary cancer for adults treated
for pituitary adenoma. [67] They compared IMRT and proton treatment plans with
different numbers of treatment fields. The overall excess number of secondary cancer
cases was 25 per 10,000 patients treated with IMRT and 20.4 per 10,000 patients
treated with proton therapy. However, they found that proton therapy would cause a
higher excess risk of secondary tumor if the treatment plan called for more than two
fields. Namely, 2-field IMRT treatment resulted in a 9.8 per 10,000 patients excess
risk, compared to 12, 15, and 16 per 10,000 patients for 3-field, 4-field, and 5-field
proton therapy treatment respectively.
The largest clinical study so far investigating the risk of secondary cancer from
proton therapy was conducted at the Massachusetts General Hospital (MGH). [68]
Preliminary and as of yet unpublished results from this study found that the incidence
of secondary cancer 15 years after treatment was 7% for proton therapy and 20% for
photon therapy. [68] The study followed a group of 488 proton patients and 488 photon
patients, treated for all types of tumors. Patients had a median age of 56 years for
the proton cohort and 59 years for the photon cohort, though both cohorts included
pediatric patients. The study adjusted for gender and age at treatment.
3.5 Cost-Effectiveness Analysis of Proton Therapy
for the Treatment of Pediatric Tumors
There are currently only a few published studies that investigate the cost-effectiveness
of proton therapy compared to conventional photon therapy and/or IMRT. [19] [69] [70]
The study most relevant for the work in this thesis is Lundkvist et al's cost-effectiveness
analysis of proton therapy for the treatment of pediatric medulloblastoma. [19] The
group designed a Markov model to simulate two groups of children receiving proton
therapy or conventional photon therapy in Sweden. Their model included seven types
of long-term health effects: hearing loss, IQ loss, hypothyroidism, GHD, osteoporosis,
cardiac disease, and secondary cancer. Lundkvist et al estimated the risks of healths
effects based on a review of literature and the costs were estimated for a Swedish
pediatric population. Their model found that proton therapy resulted in E23,600 in
cost savings. IQ loss and GHD were the main contributors to the cost savings.
The model in this thesis updates the work by Lundkvist et al by estimating the
risk of long-term health effects from the analysis of patient treatment plans, using
existing models that relate dose to risk of health effects. Results of more recent
clinical studies of pediatric proton patients are also used. Furthermore, the costs in
this model are updated to apply to a U.S. pediatric population. The next chapter
describes the treatment plan analysis and model design in detail.
Chapter 4
Methodology
This chapter explains the method applied to evaluate the health effects and costs of
proton therapy and IMRT. The analysis involved a four-step process (Figure 4-1):
1. Literature review and MGH staff interviews.
2. Analysis of patient treatment plans.
3. Estimation of risks and costs of long-term health effects.
4. Design of a Markov model to simulate pediatric populations treated for LGGs
with proton therapy and IMRT.
The findings of the literature review and MGH staff interviews were described
in Chapter 3. This chapter explains how process 2 through 4 were accomplished.
The first section details how proton and IMRT treatment plans from pediatric LGG
patients were collected and analyzed to determine the risks of IQ loss and hearing loss.
A Markov model was designed to determine the long-term health effects and costs
that are incurred by pediatric LGG survivors throughout their lifetime. The Markov
model was evaluated as a Monte Carlo simulation to determine the prognoses of a large
number of individual patients. Section 4.2 describes the model in details, explaining
how the health risks and their associated costs were determined and applied.
Figure 4-1: Flow chart of the methods applied in the analysis of the long-term health
effects and costs of proton therapy and IMRT
4.1 Patient Treatment Plans
Four patient treatment plans were obtained from the Massachusetts General Hospital
(MGH) for analysis. The patients were chosen based on two criteria:
1. Pediatric patient diagnosed with LGG.
2. Both proton therapy and IMRT treatment plans were designed for each patient.
The treatment plans from two of the patients were used for the full analysis, while
the other two were used only for further IQ change analysis. The two patients used
for the full analysis were the only cases that had both IMRT and proton plans with
all of the necessary brain structures outlined. In this document, they are referred
to as P1 and P2. P1 was a female patient age 8 with a pilocytic astrocytoma. P2
was a female patient age 5 with a posterior fossa ependymoma. Two more patient
treatment plans were added after initial analysis of the results to investigate further
the difference in IQ loss between proton therapy and IMRT. P3 was a male patient
age 7 with a craniopharyngioma. P4 was a male patient age 14 with a LGG. All of
the patients were treated at the Francis H. Burr Proton Therapy Center at MGH
using a 240 MeV cyclotron.
Patients were treated according to a Local Protocol #10-206, developed at MGH
as part of a follow-up study of patients treated for pediatric brain tumors using proton
therapy to determine their long-term health effects. [71] For LGG, a dose of 50.4-54
Gy was delivered to the tumor volume. The full dose was delivered in 1.5-2.0 Gy
fractions (typically 1.8 Gy/fraction), 5 days per week.
The treatment plans were developed using XiO@ treatment planning software.
The gross target volume (GTV) was defined as any gross disease visible on the MRI.
The clinical target volume (CTV) was defined as a 3-7.5 mm expansion of the tumor,
based on the physician's judgment of the extent of microscopic disease. Figure 4-2
shows images generated in XiO@ from P1's treatment plans. The XiO® images for P1
and P2 are available in Appendix A. The red line represents the contour of the tumor
volume. All the other contour lines are isodose lines that indicate which volume of
the brain received the associated dose level. For example, any volume inside of the
magenta isodose line received 4,500 cGy or higher in the proton treatment plan and
4,000 cGy or higher in the IMRT treatment plan shown in Figure 4-2.
4.1.1 Dose-Volume Histograms
Dose-Volume Histograms (DVHs) were calculated for a specific set of structures asso-
ciated with the risk of adverse health outcomes, as listed in Table 4.1. The DVH's are
graphs of the dose delivered to a volume of the brain. Specifically, cumulative DVHs
show the percentage volume of a structure that received x dose (in Gy) or higher.
For example, Figure 4-3 shows that 46.3% of the supratentorial brain received 20
Gy or higher. The data from the DVHs were used to determine the risks of IQ loss
and hearing loss. The models from literature used to calculate those health risks are
explained in the next section.
Table 4.1: Brain structures related to health outcomes
Brain Structure Health Outcome
Whole brain Secondary Cancer
Supratentorial brain IQ Loss
Left Temporal Lobe IQ Loss
Hypothalamus GHD, Hypothyroidism
Pituitary Gland GHD, Hypothyroidism
Cochlea (left and right) Hearing Loss
(a) Proton therapy - axial view
(c) Proton therapy - coronal view
(e) Proton therapy - sagittal view
(d) IMRT - coronal view
(f) IMRT - sagittal view
Figure 4-2: P1 Proton therapy and IMRT treatment plans, as seen from the axial,
sagittal, and coronal views. The red contour line delineates the GTV. A compari-
son of the images show that proton therapy provides an improved dose distribution
compared to IMRT by irradiating less brain tissue around the target.
(b) IMRT - axial view
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Figure 4-3: Cumulative DVH of supratentorial brain from an IMRT treatment plan.
The dashed line helps to indicate the example point that 46.3% of the supratentorial
brain received 20 Gy or higher.
4.2 Cost-Effectiveness Model
The cost-effectiveness model in this thesis was designed as a Markov Model using the
TreeAge Pro 2009 software. Markov models are decision models designed to account
for events that recur over time. [72] Markov models are useful when trying to make
decisions about healthcare strategies; in this case, whether to treat LGGs with proton
therapy or IMRT.
In a Markov model, a patient is always in one of a set number of health states
during each cycle. In that state, the patient experiences various events (for example,
getting a secondary cancer) according to the model design. At the end of each cycle,
the patient may transition between the health states. A cycle is a length of time during
which the patient stays in a particular health state. For a model that evaluates the
lifetime of a population, the cycle time is typically one year. If the patient dies during
a given cycle, the patient is sent to the death state. The death state is a terminal
state, effectively ending the simulation for that patient.
The model in this thesis was designed to track two hypothetical cohorts of pediatric
patients treated for LGGs, one cohort with proton therapy and the other with IMRT.
The pediatric patient cohort was evaluated starting at age 5. Each patient's gender
was determined at the beginning of the simulation, and the patient was evaluated
using the associated gender-specific risks and costs.
The model was designed as a Monte Carlo simulation, where a large number of
patients faced with the same health risks are individually tracked. Every cycle, the
patient is put in the 'Survive' state where he or she runs the risks of experiencing
various adverse health outcomes with their associated costs. The patient goes through
the simulation until he/she dies based on the mortality risks detailed below, in which
case the patient reaches the terminal 'Death' state.
The Monte Carlo simulations in this model was test with a sample size of 100,000
patients. Each cycle was set to be 1-year. Every cycle, each patient was faced
with probabilities of gaining a long-term health effect and dying. Each patient could
experience the following health outcomes: IQ loss, GHD, hypothyroidism, hearing
loss, and secondary cancer. The patient also ran the risk of death, with the possibility
of dying from normal death, tumor recurrence death, or secondary cancer death.
Whenever the patient reached the end of a cycle, all their costs incurred that year
would be added to the costs from previous years. The patient would run through the
model until death, which was forced at age 100 if the patient did not die before then.
4.2.1 Mortality Risks
The model assumed 5 and 10 year survival rates of 98.5% and 95.9%, according to
Merchant et al's LGG study. [51] The mortality rate also included a 20-year survival
rate of 85% from a follow-up study of 71 pediatric LGG patients between 1956 and
1991. [73] The overall 5-year, 10-year, and 20-year mortality probabilities were 1.5%,
4.1%, and 15% respectively.
Risk of dying from secondary cancer was included from year 1-15 after diagnosis,
as shown in Table 4.2. Patients could only incur the risk of secondary cancer death
if they had secondary cancer that particular cycle.
Table 4.2: Yearly risk of death due to secondary cancer
Time From Treatment (years) Probability
1-10 0.13%
11-15 0.12%
The secondary cancer mortality rate was based on the mortality data from the
Childhood Cancer Survivor Study. [34] The data are based on the mortality experience
of 20,483 U.S. pediatric cancer survivors as of 2002. The CCSS study did not provide
risks of death from tumor recurrence for the first four years as the patients were only
evaluated starting from 5 years after treatment. In the model, the risk of death due
to secondary cancer from years 1-4 after treatment was assumed to be the same as
the rate from years 5-10.
Beginning fifteen years after treatment (in the base case, from age 21 on), nor-
mal death rates for males and females were applied according to the 2006 U.S. Life
Tables. [74]
4.2.2 Risks of Health Outcomes
IQ Loss
The average IQ loss was estimated using the study by Merchant et al, which followed
a group of 78 LGG pediatric patients treated with radiation therapy (all photon). [42]
The study quantified the relationship between radiation dose and IQ score, as shown
in Equation 4.1:
IQ = 95.5545+Age x 0.3291+Timex (Age x 0.00273-V- 30 x 0.0027- V30-ro x 0.0047)
(4.1)
where Age is the age in years when the patient receives radiation treatment, Time is
the time in months since radiation treatment, V- 0 is the percentage of supratentorial
brain that received 0 to 30 Gy, and V30-o is the percentage of supratentorial brain
that received 30 to 60 Gy.
The number of IQ points lost was determined using Equation 4.1, with the volume
inputs taken from the DVHs of the supratentorial brain for proton therapy and IMRT.
Merchant et al's analysis did not specify the uncertainty associated with the IQ score
calculated form Equation eq:Merch-dose-IQ. However, since Merchant et al found
that their model could predict IQ score after radiation treatment, the model in this
thesis assumed that any difference found in IQ score was significant.
Since the Merchant et al study followed the patients' IQ change only up to 5 years
after treatment, this model presented here assumed all IQ loss occurs up to 5 years
after treatment. The base case assumed that all proton therapy and IMRT patients
acquired the full IQ loss calculated using Equation 4.1.
Endocrine Dysfunctions
The model included the risk of GHD and hypothyroidism. For proton therapy, the
cumulative 10-year risk of GHD and hypothyroidism were both estimated at 35%,
assuming a constant yearly incidence rate of 0.005/person-year. The study by Hug
et al of 25 pediatric patients treated for LGG using proton therapy found 4 patients
(17%) with endocrine complications 3 years after treatment. The follow-up study
(n= 116) by Dr. Margaret Pulsifer at MGH found a 21% (n = 24) risk of developing
endocrine problems for patients any time between 1 to 10 years post-treatment. The
risks of GHD and hypothyroidism in this model were higher than the ones in literature
to provide a conservative estimate.
For IMRT, the 10-year GHD and hypothyroidism risks were estimated at 49%
and 68%, respectively, based on Merchant et al's study. [51] The model assumed
that the rate of GHD and hypothyroidism incidence were constant over the 10 years
post-treatment (0.006/person-year and 0.01/person-year).
After year 10 (after treatment), the risk of GHD and hypothyroidism were reduced
to 0%. This assumption was made in the model as not enough reliable data was
available beyond the 10-year follow-up. Furthermore, the model assumed that ten
years after treatment, patients would be 15 years old and would no longer need to
receive growth hormones since growth hormone therapy usually ends for children
during their mid to late teenage years. [58]
Growth hormone therapy was terminated after age 16 for males and age 14 for
females, as the accepted ages when children reach their final height. [58] Studies have
shown that a certain number of the patients who received growth hormone therapy
as children are still growth hormone deficient when they reach adulthood. [51] [57]
However, those patients do not often receive growth hormone treatment even though
they might need it as they are not tested for GHD at their final height.
Hearing Loss
The risk of hearing loss was based on a study by Chiaho Hua et al relating hearing
loss to the cochlea dose given to pediatric patients treated for brain tumors. [44] The
risk of hearing loss varied according to mean dose delivered to cochlea, as shown in
Table 4.3.
Table 4.3: Risk of hearing loss based on average dose to cochlea
Dmean Risk
less than 35 0%
35-44 0-16%
45-54 0-20%
55 and higher 17-49%
All cases of hearing loss were assumed to occur on year 3 after treatment, based
on the Hua et al study that found most hearing loss onset at year 3.3. The model
used a uniform risk based on Table 4.3 of acquiring a hearing loss on either ear.
Secondary Cancer
The risk of secondary cancer was based on the study by Winkfield ??, which modeled
the risk of secondary cancer for proton therapy and IMRT. [67] In this model, the
yearly probability of secondary cancer was 0.12% for proton therapy and 0.18% for
IMRT. The probability of getting secondary cancer at each cycle is defined in Table
4.4. The probabilities of secondary cancer were based on Winkfield et al's results for
3-field treatments.
The risk of getting a secondary cancer was set to zero at 15 years after treatment.
Follow-up data of patients beyond 15 years after treatment are difficult to obtain, and
the current clinically studies published on the risk of secondary cancer generally only
provide confident estimates up to 10 years after treatment. [66] [68] In this model,
each patient could only get secondary cancer once in their lifetime.
Table 4.4: Yearly sisk of secondary cancer for proton therapy and IMRT
Time Since Treatment (Years) Proton IMRT
1-15 0.12% 0.18%
16+ 0% 0%
4.2.3 Costs Estimation
Proton and IMRT Treatment
The cost of proton therapy was estimated at $58,000/treatment. A recent study by
Peeters et al found that the treatment of head and neck tumors was e39,610, or
$58,971 in 2011 dollars, for proton therapy. [75] The cost-effectiveness analysis of
proton therapy for prostate cancer also estimated the cost at $58,000/treatment. [70]
Proton beam therapy is generally accepted at being twice as expensive as IMRT.
A cost study by by Goitein and Jermann estimated the proton therapy/IMRT cost
ratio at 2.1. [12] The model used the 2.1 cost ratio as the base case, estimating the
cost of IMRT at $24,000/treatment. Peeters et al found a ratio of 3.2 for the cost
ratio, and this value was used in the sensitivity analysis. [75]
IQ Loss
The cost of IQ loss is associated with income loss. The yearly income loss was set
at 1.931%/IQ point for men and 3.225%/IQ point for women. The average income
used was $45,485/year for men and $35,549/year for women, according to the U.S.
Census Bureau Report for 2009. [76] Income loss occured from age 18 to 65. The rates
of income loss due to IQ loss were based on a study by Salkaver that reviewed the
expected earning loss from children affected by lead poisoning. [77] Those children
were likely to have a lower IQ depending on the lead dose, which in turn negatively
impacted their education and earning potential.
The general threshold for an individual to be considered intellectually disabled is
an IQ score of 70 or lower. [78] In this model, the cost of IQ loss also included the cost
of special education from age 4 to 18 if the patients' IQ score was 70 or below. The
cost of special education was estimated at $15,000/child-year. The U.S. Department
of Education evaluated a cost of $12,474/child-year in in their 2002 report, which is
roughly equivalent to $15,000 in 2011 dollars.[79]
Endocrine Dysfunctions
The cost associated with GHD varies between $5,000-$27,000/year, based on the cost
of Omnitrope and Tev Tropin ($30/mg). [80] The GH dose prescribed is 0.3 mg/kg-
week, based on the patient's weight. [81] Using weight charts for American males and
females, the prescribed dose and cost was determined for each age, as shown in Table
4.5. [82]
Males receive a dose of 0.3 mg/kg-week up to age 16. Females receive a dose of
0.3 mg/kg-week up to age 14. After that age, the dose drops to 10% of the original
prescription or 0.03 mg/kg-week. The base case assumed that patients stopped taking
growth hormones at age 16 for males and age 14 for females, which is when they
typically stop growing.??
Table 4.5: Yearly GHD costs by age
population
Male
Dose
(mg/week)
4.0
4.6
5.2
5.9
6.6
7.3
8.1
9.1
10.2
11.4
12.9
14.5
16.1
17.6
18.9
based on the 50th percentile weight of the U.S.
Cost
($/year)
5,803
6,590
7,472
8,437
9,445
10,511
11,690
13,046
14,629
16,472
18,573
20,860
23,188
25,347
27,145
Weight
(kg)
12.8
14.7
16.7
18.9
21.3
23.9
27.0
30.6
34.7
39.1
43.4
47.4
50.6
Female
Dose
(mg/week)
3.8
4.4
5.0
5.7
6.4
7.2
8.1
9.2
10.4
11.7
13.0
14.2
15.2
The cost of hypothyroidism was $168/year, based on the cost of the generic drug
Levothyroxine Sodium at $14/month for a dose of 75 mcg/day.?? The cost of the
generic drug was used to assume the least costly scenario. Patients needing thyroid
hormone replacement had a yearly recurring cost until death.
Patients with endocrine complications saw an endocrinologist on average 3 times
per year. [58] The model included physician costs for patients with either GHD or
hypothyroidism (Table 4.6). The physician costs were derived from interviews re-
questing consultation quotes from MGH and the Mayo Clinic. [58] [83]
Hearing Loss
The cost of a hearing aid was estimated at $2,500/ear, with the cost recurring ev-
ery 5 years. [84] An additional audiologist visit cost of $750 also recurred every 5
years. The values were based on an interview requesting consultation quotes from
Age
(years)
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Weight
(kg)
13.4
15.3
17.3
19.5
21.9
24.3
27.1
30.2
33.9
38.1
43.0
48.3
53.7
58.7
62.8
Cost
($/year)
5,539
6,329
7,201
8,155
9,186
10,333
11,658
13,208
14,975
16,874
18,758
20,459
21,837
Table 4.6: Costs of visits to endocrinologist
Cost/Visit # of Visits Total
Year 1 Consultation $816 1
Year 1 Follow-Up $280 2 $1376
All other years Follow-Up $280 3 $840
the Massachusetts Eye and Ear Hospital. [85]
Secondary Cancer
The cost of secondary cancer was $24,143/case based on the average cost of pediatric
secondary cancer cases in the U.S. (cost was updated from $21,100 in 2005 to 2011
currency). [86] [87]
4.3 Sensitivity Analysis
To test the robustness of the results, certain parameters in the model were changed.
The sensitivity analysis varied three aspects of the model: 1) mortality rates based
on tumor recurrence data from the Childhood Cancer Survivor Study, 2) costs of
radiation treatment, and 3) costs of GHD treatment based on higher average weight
estimates. The sensitivity analysis was applied to the models using P1 and P2 input
data holding everything constant except for the specific change of interest. Only one
parameter was varied at a time.
Tumor Recurrence Rate
The mortality risk was changed to include mortality data from the Childhood Cancer
Survivor Study. [34] The data is based on the mortality experience of 20,483 U.S.
pediatric cancer survivors as of 2002. The risk of death due to tumor recurrence for
all cancer patients were used from year 5-34 after diagnosis, as shown in Table 4.7.
The yearly risk of death estimated in Table 4.7 included both the risk of tumor
Table 4.7: Yearly risk of death due to tumor recurrence
Time From Treatment (years) Risk
5-10 1.02%
11-14 0.46%
15-19 0.35%
20-24 0.35%
25-29 0.44%
30-34 0.68%
recurrence and 'other' death from the Armstrong et al study. [34] The risk of 'other'
death included any patients who died from reasons that were not due to secondary
cancer, tumor recurrence, cardiac,pulmonary, and external causes. The CCSS study
did not provide risks of death from tumor recurrence for the first four years as the
patients were only evaluated starting from 5 years after treatment. From year 1-4
after treatment, this model assumed that the risk of death due to tumor recurrence
were the same as in the base case.
Five years after treatment (from age 16 on), normal death rates for males and
females were also applied according to the 2006 US Life Tables. [74] The normal
death rates were used to account for any death unrelated to the tumor.
Cost of Radiation Treatment
A study by Goitein and Jermann determined the cost of treatment per fraction to be
p1025 for protons and 6425 for IMRT (in 2003 currency). [12] Assuming an average
conversion rate of $1 to I1.07 in 2003, the cost per fraction is $1160 for proton therapy
and $481 for IMRT (in 2011 dollars). [88] [87] For a 30-fraction LGG treatment, the
cost of proton therapy and IMRT was estimated at $35,000 and $15,000 respectively
in the sensitivity analysis. Another analysis tested the 3.2 proton therapy/IMRT
cost ratio estimated by Peeters et al., with cost of treatment estimated at $58,000 for
proton therapy and $18,000 for IMRT.
Higher GHD Costs
Studies have shown that there is an increased chance of obesity in pediatric population
treated with radiation therapy. [89] [90] The Childhood Cancer Survivor Study that
leukemia survivors treated with 20 Gy CRT were more likely to be obese than the gen-
eral population (2.72 times higher for females, 1.66 times higher for males). [91] The
patients weight was increased to match the average of children in the 75thpercentile
weight of the US population. The costs of growth hormone therapy were updated to
match the higher weights, as shown in Table 4.8.
Table 4.8: Yearly GHD costs by age based on the 75th percentile weight of the U.S.
population
Male
Dose
(mg/week)
4.3
5
5.7
6.4
7.3
8.1
9.1
10.3
11.6
13.1
14.8
16.6
18.4
19.9
21.3
Cost
($/year)
6254
7141
8156
9279
10462
11726
13145
14796
16725
18934
21370
23926
26441
28723
30611
Weight
(kg)
13.9
16.0
18.4
21.0
23.8
26.9
30.7
35.0
40.0
45.1
50.1
54.5
57.9
Female
Dose
(mg/week)
4.2
4.8
5.5
6.3
7.1
8.1
9.2
10.5
12
13.5
15
16.3
17.4
This chapter describes the methods used in this study to compare proton therapy
and IMRT. The following chapter provides the long-term health effect and cost results
from the model simulations based on P1 and P2's treatment plans. The results from
the sensitivity analysis and IQ analysis of patients P3 and P4 are also presented.
Age
(years)
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Weight
(kg)
14.5
16.5
18.9
21.5
24.2
27.1
30.4
34.3
38.7
43.8
49.5
55.4
61.2
66.5
70.9
Cost
($/year)
5989
6911
7935
9051
10266
11639
13248
15134
17259
19498
21659
23539
24992
56
Chapter 5
Results
In this chapter, the results of the Markov model described in Chapter 4 are pre-
sented, and conclusions based on the expected long-term health effects and costs
incurred from proton therapy and IMRT are discussed. The first two sections present
the results of the model simulations based on P1 and P2 treatment plans, compar-
ing the health effects and costs associated with the two treatment modalities. The
final section further explores the relative difference in total IQ loss between the two
modalities using treatment plans from patients P3 and P4.
All costs are presented to the nearest thousands of dollars as the cost results are
not significant to the hundreds of dollars or lower. The rounding of the results does
not influence the conclusions of this thesis.
5.1 Results using P1's Proton Therapy and IMRT
Treatment Plans
The modeled change in IQ score for P1 was considerable for both proton therapy and
IMRT (Figure 5-1). From a starting point of IQ = 97, the IQ score drops to 80 points
for proton therapy and 78 points for IMRT. The relative difference in total IQ loss
between modalities was small, with IMRT overall incurring an additional 2-point loss
compared to proton therapy (Table 5.1).
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Table 5.1: P1 Estimated IQ points loss after receiving radiation treatment at age 5
Time since CRT IQ Loss (pts)
(months) Proton Therapy IMRT
12 3 4
24 7 8
36 10 12
48 14 15
60 17 19
Table 5.2 shows the Vo-30 and V30- 60 split for supratentorial brain. Proton therapy
delivers a high dose (30-60 Gy) to a lesser volume of the supratentorial brain than
IMRT. Based on P1's cochlea DVH data, the risk of hearing loss was 0% for both
proton therapy and IMRT (Table 5.3).
The model found that proton therapy always resulted in a lower risk of acquiring
a long-term health effect for GHD, hypothyroidism, and secondary cancer, as shown
in Table 5.4. There was no difference in risk of hearing loss (Table 5.3). In the
- PT IQ (Age 5)
IMRT IQ (Age 5)
ng radiation
Table 5.2: Volume of supratentorial brain that received 0-30 Gy and 30-60 Gy based
on P1's treatment plans
Proton Therapy
IMRT
V- 30
85%
67%
V30-6o
15%
33%
Table 5.3: P1 risk of hearing loss
Mean Dose (Gy) Risk
Proton Therapy Right Cochlea 3 0%
Left Cochlea 2 0%
IMRT Right Cochlea 21 0%
Left Cochlea 15 0%
simulation, the model assigned IQ loss estimated for P1 to all patients.
Table 5.4: P1 Modeled risks of long-term health effects
IQ GHD Hypothyroidism Hearing Secondary
Loss Loss Cancer
Proton Therapy 100% 32% 32% 0% 2%
IMRT 100% 43% 56% 0% 3%
Difference 0% -10% -23% 0% -1%
The model found a large lifetime cost associated with long-term health effects:
an average of $349,000/patient for proton therapy and $365,000/patient for IMRT
(Table 5.5). IMRT was found to be more expensive with an average cost difference
of $17,000/patient (Table 5.5). The majority of the total cost was due to IQ loss
($246,000/patient for proton therapy and $275,000/patient for IMRT), reflecting that
a small change in IQ points could lead to a significant long-term cost difference. If IQ
loss is not considered in the cost comparison, proton therapy was found to be more
expensive than IMRT by $12,000/patient.
Table 5.5: P1 Total cost comparison between proton therapy and IMRT
Proton Therapy ($) IMRT ($) Difference ($)*
Treatment Cost 58,000 28,000 30,000
IQ Loss 246,000 275,000 -29,000
Endocrine Dysfunction 44,000 62,000 -18,000
Hearing Loss 0 0 0
Secondary cancer 400 500 -200
Total 349,000 365,000 -17,000
Total without IQ 102,000 90,000 12,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
Endocrine dysfunction was the second largest driver of cost ($32,000/patient for
proton therapy and $44,000/patient for IMRT), with GHD contributing the largest
proportion of that cost (Table 5.6).
Table 5.6: P1 Detailed endocrine dysfunction cost comparison between
proton therapy and IMRT
Proton Therapy ($) IMRT ($) Difference ($)*
GHD 32,000 44,000 -12,000
Hypothyroidism 1,000 2,000 -1,000
Endocrinologist Visit 11,000 16,000 -5,000
Total 44,000 62,000 -18,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
For proton therapy, the breakdown of total costs shows that the majority of the
total costs incurred by each patient fall in the $240,000-480,000 range (Figure 5-2).
That range of high costs in Figure 5-2 reflect the costs accumulated from IQ loss
for the patients who did not experience death due to tumor recurrence or secondary
cancer. That population represents 85% of the total sample population, as shown in
Table 5.7. Those patients lived to be on average 70 years old and incurred the full
cost of IQ loss from age 18-65. With a 17 points IQ loss, the maximum lifetime cost
associated with IQ loss is $219,482 for males and $286,487 for females. The maximum
lifetime GHD cost is $159,632 for males and $139,367 for females. The low total costs
(below $240,000) reflect the population that dies early. Costs savings occur when the
population dies early as an artifact of the model, which will be discussed in Chapter
6.
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Figure 5-2: P1 Probability of total cost per patient due to
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Table 5.7: P1 Risk of normal death, tumor recurrence death,and secondary cancer
Normal Death Tumor Recurrence Secondary Cancer
Proton 85.6% 14.3% 0.1%
IMRT 84.3% 14.2% 0.1%
The risk of secondary cancer death was low because patients could only face that
risk once they acquired a secondary cancer. However, the results show that there is
only a small chance of secondary cancer in a patient's lifetime (2% for proton therapy
61
and 3% for IMRT). Consequently, the risk of death due to secondary cancer is very
low (0.1% for both treatment modalities).
For IMRT, the individual breakdown of total costs shows that the majority of
the total costs incurred by each patient fall in the $300,000-480,000 range (Figure
5-3). That cluster of high costs (greater than $300,000) reflects the population that
live beyond the risk of death due to tumor recurrence and secondary cancer. The
population who survive past age 25 face normal death rates and survive until an
average age of 70. With a 19-point IQ loss, the maximum lifetime IQ cost is $245,303
for males and $320,191 for females.
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Figure 5-3: P1 Probability of lifetime cost per patient due to
from IMRT treatment
long-term health effects
5.2 Results using P2's Proton Therapy and IMRT
Treatment Plans
The expected change in IQ score for P2 is high for both proton therapy and IMRT
(Figure 5-4). From a starting score of IQ = 97, the IQ score dropped to 82 points
for proton therapy and 81 points for IMRT. The relative difference in total IQ loss
between modalities is small however, with IMRT overall incurring an additional 1-
point loss compared to proton therapy (Table 5.8).
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Table 5.9 shows the V-3 0 and V30 -6 0 split for the supratentorial brain. Proton
therapy delivers a higher dose (30-60 Gy) to a lesser volume of the supratentorial
brain than IMRT. Based on P2's cochlea DVH data, the risk of hearing loss was 0%
for proton therapy and 0-16% for IMRT (Table 5.10), according to the study by Hua
et aL [44] The model found that proton therapy always resulted in a lower incidence
of long-term health effects for GHD, hypothyroidism, secondary cancer, and hearing
loss as shown in Table 5.11.
Table 5.8: P2 Estimated IQ points loss after receiving radiation treatment at age 5
Time since CRT Proton Therapy IMRT
(months) (pts) (pts)
12 3 3
24 6 7
36 9 10
48 13 14
60 16 17
Table 5.9: Volume of supratentorial brain that received
on P2's treatment plans
0-30 Gy and 30-60 Gy based
Vo-3o V30-6o
Proton Therapy 97% 3%
IMRT 87% 13%
Table 5.10: P2 Risk of hearing loss
Mean Dose (Gy) Risk
Proton Therapy Right Cochlea 2 0%
Left Cochlea 7 0%
IMRT Right Cochlea 35 0-16%
Left Cochlea 35 0-16%
Table 5.11: P2 Modeled risks of long-term health effects
IQ GHD Hypothyroidism Hearing Secondary
Loss Loss Cancer
Proton Therapy 100% 32% 32% 0% 2%
IMRT 100% 43% 56% 8% 3%
Difference 0% -10% -23% -8% -1%
For P2, the model found an average cost associated with long-term health effects
of $334,000/patient for proton therapy and $343,000/patient for IMRT (Table 5.12).
IMRT was more costly, with an average cost difference of $9,000/patient (Table 5.12).
The majority of the total cost was due to IQ loss ($232,000/patient for proton therapy
and $246,000/patient for IMRT). The overall cost from IQ loss was lower than ob-
served in the P1 simulation since P2's treatment plans resulted in a higher estimated
IQ score for both proton therapy and IMRT. Furthermore, the difference in IQ loss
cost between proton therapy and IMRT for P1 and P2 ($29,000/patient for P1 and
$14,000/patient for P2) reflects the difference in costs expected from a change of 1
IQ point - i.e roughly $14,000/patient per IQ point. If IQ loss is not considered in
the P2 cost comparison, proton therapy was found to be more expensive than IMRT
by $5,000/patient. The total difference without consideration of IQ loss was lower for
P2 than for P1 because the P2 IMRT patients incurred an extra cost from hearing
loss. Endocrine dysfunction was the second largest driver of cost ($44,000/patient
for proton therapy and $62,000 for IMRT), with GHD contributing to the largest
proportion of that cost (Table 5.13). The risks of death were the same for the P1 and
P2 simulations (Table 5.14).
Table 5.12: P2 Total cost comparison between Proton Therapy and IMRT
Proton Therapy ($) IMRT ($) Difference ($)*
Treatment Cost 58,000 28,000 30,000
IQ Loss 232,000 246,000 -14,000
Endocrine Dysfunction 44,000 62,000 -18,000
Hearing Loss 0 7,000 -7,000
Secondary cancer 400 500 -200
Total 334,000 343,000 -9,000
Total without IQ 102,000 97,000 5,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
For proton therapy, the breakdown of total lifetime costs shows that the majority
of the total costs incurred by each patient fall in the $240,000-420,000 range (Figure
5-5). The maximum lifetime IQ loss costs from a 16-point drop is $206,571 for males
and $269,635 for females. The individual breakdown of total costs shows that 75% of
the total costs incurred by each patient fall in the $240,000-480,000 range for IMRT
Table 5.13: P2 Detailed endocrine dysfunction cost comparison between
proton therapy and IMRT
Proton Therapy ($) IMRT ($) Difference ($)*
GHD 31,000 43,000 -12,000
Hypothyroidism 1,000 2,000 -1,000
Endocrinologist Visit 11,000 16,000 -5,000
Total 44,000 62,000 -18,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
(Figure 5-6). The cluster of high costs (greater than $300,000) reflects the population
that pass the risk of death due to tumor recurrence and secondary cancer.
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Figure 5-5: P2 Probability of lifetime cost per patient due to long-term health effects
from proton therapy.
The results based on P1 and P2's treatment plans show that proton therapy is the
dominant treatment modality. Proton therapy results in lower incidences of long-term
Table 5.14: P2 Risk of normal death, tumor recurrence deathand secondary cancer
Proton Therapy
IMRT
Normal Death
85.6%
85.5%
Tumor Complications
14.3%
14.3%
Secondary Cancer
0.1%
0.1%
Probability
--10/50/90 percentile
moil
0 60 120 180 240 300 360 420 480 540 600
Cost (thousands $)
Figure 5-6: P2 Probability of lifetime cost per patient due to
from IMRT
long-term health effects
health effects and expected overall lower costs than IMRT, by $17,000/patient based
on P1's estimated health risks and $9,000/patient based on P2's estimated health
risks. The cost associated with IQ loss was the main driver of total costs. However,
the relative difference in IQ between proton therapy and IMRT was small for both
patients (a 2-point difference in IQ score for P1 and a 1-point difference in IQ score
for P2).
5.3 Sensitivity Analysis
The sensitivity analysis varied particular aspects of the model, namely:
1. Mortality rates based on tumor recurrence data from the Childhood Cancer
Survivor Study.
2. Costs of radiation treatment.
3. Costs of GHD treatment based on higher average weight estimates.
The sensitivity analysis was applied to the models using P1 and P2 health risks,
holding everything constant except for the specific change of interest. Only one
parameter was varied at a time.
5.3.1 Tumor Recurrence Rate
The initial analysis assumed mortality rates due to tumor recurrence or tumor related
complications for up to 20 years after treatment. The first variation on the base case
applied higher mortality rates due to tumor recurrence based on the Childhood Cancer
Survivor Study for up to 34 years after treatment. Patients lived on average until age
60 for the CCSS tumor rate case and age 70 for the base case. Patients in the higher
mortality rates case were subjected to fewer long-term costs since they had died and
the cost of reduced IQ was no longer accrued. The average lifetime cost per patient
was $325,000 for proton therapy and $338,000 for IMRT for the case of higher tumor
recurrence rate using the P1 simulation (Table 5.15). The cost savings were not as
high in the sensitivity analysis as fewer patients experienced the higher range of IQ
loss cost. In the base case, since the patients lived longer, they were subjected to
higher IQ loss costs.
The average lifetime cost per patient was $312,000 for proton therapy and $320,000
for IMRT for the case of higher tumor recurrence rate using the P2 simulation(Table
5.16). The cost savings were not very different between the higher tumor recurrence
case and base case: $7,000/patient compared to $9,000/patient in the base case.
Table 5.15: P1 Comparison of total costs between base case and case with higher
probability of death due to tumor recurrence
High Recurrence Rate Base Case
PT IMRT Diff.* PT IMRT Diff.*
($) ($) ($) ($) ($) ($)
Treatment Cost 58,000 28,000 30,000 58,000 28,000 30,000
IQ Loss 224,000 250,000 -26,000 246,000 275,000 -29,000
Endocrine Dysfunction 43,000 61,000 -17,000 44,000 62,000 -18,000
Hearing Loss 0 0 0 0 0 0
Secondary cancer 400 500 -200 400 500 -200
Total 325,000 338,000 -13,000 349,000 365,000 -17,000
Total without IQ 102,000 89,000 13,000 102,000 90,000 12,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
Table 5.16: P2 Comparison of total costs between base case and case with higher
probability of death due to tumor recurrence
High Recurrence Rate Base Case
PT IMRT Diff.* PT IMRT Diff.*
($) ($) ($) ($) ($) ($)
Treatment Cost 58,000 28,000 30,000 58,000 28,000 30,000
IQ Loss 211,000 224,000 -13,000 232,000 246,000 -14,000
Endocrine Dysfunction 43,000 61,000 -17,000 44,000 62,000 -18,000
Hearing Loss 0 7,000 -7,000 0 7,000 -7,000
Secondary cancer 400 500 -200 400 500 -200
Total 312,000 320,000 -7,000 334,000 343,000 -9,000
Total without IQ 102,000 96,000 6,000 102,000 97,000 5,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
5.3.2 Cost of Radiation Treatment
The second variation looked at a lower cost of radiation therapy treatment. In the base
case, the cost treatment was $58,000/patient for proton therapy and $28,000/patient
for IMRT. In this variation, the cost of proton therapy was $35,000/patient and the
cost of IMRT was $15,000/patient. The difference between the two treatments was
also lowered: $20,000 as compared to $30,000 in the base case. The lower treatment
cost difference resulted in higher cost savings for the P1 and P2 cases. However, if
the cost of IQ loss was not accounted for, only the P2 case resulted in cost savings for
proton therapy (Table 5.17). That is, when IQ loss is not considered, proton therapy
is more expensive by -$5,000.
Table 5.17: Difference in total costs for case with treatment priced at $35,000/patient
for proton therapy and $15,000/patient for IMRT
Treatment Cost
IQ Loss
Endocrine Dysfunction
Hearing Loss
Secondary cancer
Total
Total without IQ
* Difference is equal to
P1
PT IMRT
($) ($)
35,000 15,000
246,000 275,000
44,000 62,000
0 0
400 500
326,000 353,000
79,000 78,000
the cost of proton
P2
Diff.* PT IMRT Diff.*
($) ($) ($) ($)
20,000 35,000 15,000 20,000
-29,000 232,000 246,000 -14,000
-18,000 44,000 62,000 -18,000
0 0 7,000 -7,000
-200 400 500 -200
-27,000 311,000 330,000 -19,000
2,000 79,000 84,000 -5,000
therapy minus the cost of IMRT
Another case variation analyzed the effect of a higher treatment ratio between
proton therapy and IMRT. Using Peteers et al's proton therapy to IMRT cost ratio
of 3.2 ($58,000 for proton therapy and $18,000 for IMRT), the model found that
proton therapy was not cost effective for the P2 case as the average total costs were
slighty higher for proton therapy by $1,000.
5.3.3 Cost of GHD
The final sensitivity analysis used a higher average weight to calculate the cost of
GHD. Since the cost of GHD is proportional to the weight of the patient, a higher
average weight resulted in a higher cost of GHD. The higher cost of GHD was reflected
in the higher average total cost per patient: $430,000 for proton therapy and $473,000
for IMRT in the P1 case, $416,000 for proton therapy and $451,000 for IMRT in the
P2 case (Table 5.19). This higher cost associated with GHD resulted in a higher cost
savings for proton therapy. With the higher GHD costs, proton therapy is always more
Table 5.18: Difference in total costs for case with proton therapy and IMRT treat-
ment cost ratio of 3.2
P1 P2
PT IMRT Diff.* PT IMRT Diff.*
($) ($) ($) ($) ($) ($)
Treatment Cost 58,000 18,000 40,000 58,000 18,000 40,000
IQ Loss 246,000 275,000 -29,000 232,000 246,000 -14,000
Endocrine Dysfunction 44,000 62,000 -18,000 44,000 62,000 -18,000
Hearing Loss 0 0 0 0 7,000 -7,000
Secondary cancer 400 500 -200 400 500 -200
Total 349,000 356,000 -7,000 334,000 334,000 1,000
Total without IQ 102,000 81,000 22,000 102,000 88,000 15,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
cost effective than IMRT, even in the case where IQ loss is not considered. GHD cost
is the main driver of endocrine dysfunctions cost in the case where patients with a
higher average weight are considered (Table 5.20).
Table 5.19: P1 and P2 Difference in total costs based on the 75th percentile weight
of the U.S. population
P1 P2
PT IMRT Diff.* PT IMRT Diff.*
($) ($) ($) ($) ($) ($)
Treatment Cost 58,000 28,000 30,000 58,000 28,000 30,000
IQ Loss 246,000 275,000 -29,000 232,000 247,000 -15,000
Endocrine Dysfunction 126,000 170,000 -44,000 126,000 169,000 -43,000
Hearing Loss 0 0 0 0 7,000 -7,000
Secondary cancer 400 500 -200 400 500 -200
Total 430,000 473,000 -43,000 416,000 451,000 -35,000
Total without IQ 184,000 198,000 -14,000 184,000 205,000 -20,000
* Difference is equal to the cost of proton therapy minus the cost of IMRT
Table 5.20: P1 and P2 Difference in total endocrine dysfunction costs by age based
on the 75th percentile weight of the U.S. population
PT
($)
GHD 113,000
Hypothyroidism 1,000
Endocrinologist Visit 11,000
Total 126,000
* Difference is equal to the cost
P1
IMRT
($)
151,000
2,000
16,000
170,000
of proton
Diff.*
($)
-38,000
-1,000
-5,000
-44,000
therapy
PT
($)
113,000
1,000
11,000
126,000
minus the
P2
IMRT Diff.*
($) ($)
151,000 -38,000
2,000 -1,000
16,000 -5,000
169,000 -43,000
cost of IMRT
5.4 IQ Analysis on P3 and P4
The DVHs for P3 and P4 showed that there was not a large difference in the volume
of the supratentorial brain that received 30 Gy or higher between proton therapy and
IMRT (Table 5.21). That similarity between the two plans resulted in almost the
same change in IQ score (Table 5.22).
Table 5.21: Volume of supratentorial brain that received 0-30 Gy and 30-60 Gy for
P3 and P4's treatment plans
P3
Proton Therapy
98%
2%
P4
IMRT Proton Therapy
91% 78%
9% 22%
The results of the simulations showed that proton therapy decreases the risk of
long-term health effects and costs incurred in the case of the two patients analyzed
in this thesis. Costs associated with IQ loss were the main drivers of total costs.
However, the difference in IQ loss between the two modalities was not large (on the
order of 1 or 2 IQ points difference). Chapter 6 will discuss the results described in
this chapter, providing explanations for the differences in the long-term health effects
and costs between proton therapy and IMRT.
V- 30
V30-60
IMRT
65%
35%
Table 5.22: IQ score change based on P3 and P4's treatment plans
P3 P4
Time since CRT (months) Proton Therapy IMRT Proton Therapy IMRT
0 97 97 97 97
12 94 94 94 93
24 91 91 90 89
36 88 87 86 85
48 85 84 83 82
60 82 81 79 78
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Chapter 6
Discussion
In the previous chapter, proton therapy was found to reduce the incidence of long-term
health effects and their associated costs when compared to IMRT. Proton therapy was
more cost-effective than IMRT, except for the case when the cost from IQ loss was not
included or when the cost difference between the two treatment plans was increased.
This chapter provides a discussion of the long-term health and costs results, explaining
why the differences presented in Chapter 5 occurred and addressing limitations of the
current model.
6.1 Causes of Death
In this model, the patients could die from tumor death, secondary cancer death, and
normal death. The model did not include the risk of tumor death due to cardiac or
pulmonary complications. The risk of pulmonary death was included in Lundkvist
et al's cost-effectiveness study because the chest was irradiated during treatment for
medulloblastoma.[19] For LGG treatment, no chest irradiation is expected and thus
the risk of pulmonary complications is small. The risk of cardiac death could be
significant as studies have shown that pediatric brain tumor patients have an excess
risk of obesity, which could lead to diabetes and heart problems. Future health and
cost effectiveness studies should analyze obesity and cardiac complications in more
detail.
For each simulation, the wide distribution in total cost incurred by each patient
can be explained by the risks of death. Patients who died early only had a low total
cost from long-term effects (especially due to IQ loss). Patients who died later had
a higher total cost, especially if they had an endocrine dysfunction or hearing loss as
both of those health effects are associated with life-long recurring costs.
Proton therapy was more cost-effective in the base case as patients lived longer
and were faced with more recurring costs. The base case applied death rates based
on follow up studies of LGG patients specifically. [73] [42] Patients lived on average
to age 70, at which time they had incurred the whole cost associated with IQ loss
(the cost due to IQ loss was stopped after age 65). In the sensitivity analysis, death
rates based on the Childhood Cancer Survivor Study (CCSS) for all pediatric tumors
were applied. [34] The patients had a higher risk of death due to tumor complications
and only lived to age 60, on average. Cost savings changed due to the difference in
recurring costs from IQ loss, endocrine dysfunctions, and hearing loss.
6.2 IQ Loss
Since proton therapy provides a tighter dose distribution, it would be expected that
the dose difference would result in a higher IQ loss for IMRT patients. However, the
analysis of the patient treatment plans showed that there was only a small difference
in IQ loss between proton therapy and IMRT. The results found that the calculated
change in IQ score was almost the same for proton therapy and IMRT treatment
plans. The difference in IQ loss between the two treatment plans was 2 points for P1
(17 points for proton therapy vs. 19 points for IMRT) and 1 point for P2 (16 points
for proton therapy vs. 17 points for IMRT). When this phenomenon was further
explored with P3 and P4, the difference in IQ loss was only 1 point between the two
treatment modalities.
There are two possible explanations for this small difference in IQ loss. The first
is that the model used to calculated IQ change may not be appropriate for the patient
cases used. The breakdown between V 3o and V30-60 may not be sensitive enough
for patients with only a small percentage of the supratentorial brain receiving doses
of 30 Gy or higher. All cases had less than 50% of the supratentorial brain receiving
30-60 Gy. Furthermore, a more detailed version of Merchant et al's IQ score model
should be used to account for uncertainty in the IQ difference. Are the 1 or 2-point
IQ difference found in the analysis of the patient treatment plans significant? If they
are, then the results of this thesis indicate that there are significant potential savings
from reducing the risk of IQ loss.
The second explanation is that, assuming Merchant et al's method is correct,
there really is not much of a difference in IQ loss from the way patient are currently
treated. Since the protocol for designing proton therapy treatment plans did not call
for sparing of the supratentorial brain, it is possible that the proton therapy plans
used in this study were not optimized and thus did not result in a lower IQ loss when
compared to IMRT.
As stated in Chapter 3, the reason for IQ loss is still unknown. Studies that
correlate radiation therapy to IQ loss focus on the supratentorial brain or the temporal
lobe. The study by Jalali et al found that patients had a higher risk of IQ loss if the
left temporal lobe received a high dose. [92] Specifically, a dose of 43.2 Gy or higher
to greater than 13% of the brain led to a higher chance of an IQ loss greater than 10
points. If Jalali et al's finding were applied to P1, the risk of an IQ loss greater than
10 points would be 64% for both proton therapy and IMRT (Table 6.1)
Table 6.1: Risk of IQ Loss greater than 10 points based on P1's temporal lobe DVHs
Left Temporal Lobe Receiving Risk
43.2 Gy or higher
Proton Therapy 18.2% 64%
IMRT 54.6% 64%
For P2, the risk of acquiring an IQ loss greater than 10 points would be 19% for
both proton therapy and IMRT (Table 6.2). The interesting connection between the
results based on Jalali el al's study and Merchant et al's study is that there are still
no differences between the proton therapy and IMRT treatment plans in terms of
IQ loss risk. Further work should be conducted analyze the change in IQ based on
proton therapy and IMRT treatment plans from several more pediatric LGG cases.
If possible, a follow-up of the patients whose cases are analyzed should be done to
determine if the calculated IQ loss matches with the actual IQ change.
Table 6.2: Risk of IQ Loss greater than 10 points based on P2's temporal lobe DVHs
Left Temporal Lobe Receiving Risk
43.2 Gy or higher (%)
Proton Therapy 2.6% 19%
IMRT 12.9% 19%
The cost associated with IQ loss was the largest contributor to overall costs.
Furthermore, IQ was the largest contributor to the difference in costs of long-term
health effects between proton therapy and IMRT. The results of the P1 and P2
simulations show an average cost difference from IQ loss of -$14,000/IQ point, as
shown in Table 6.3.
Table 6.3: Average costs from IQ loss, IQ cost difference, and IQ points difference
comparison for P1 and P2
Case IQ Points Avg. Cost of Cost IQ Points Cost/IQ
Loss IQ Loss ($) Difference ($) Difference ($) Point ($)
P1 IMRT 19 275,000 297000 2 147500P1 PT 17 246,000 '
P2 IMRT 17 246,000 141000 1 141000
P2 PT 16 232,000 '
No patients in the model had an IQ score below the threshold of 70 points for
special education; hence, there was no special education costs associated with the
P1 and P2 analysis. Based on a $15,000/student cost of special education and a
discount rate of 3%, the special education cost of a child attending school from age
5-18 can amount up to $159,524. A difference between proton therapy and IMRT
in the population needing special education could lead to very high cost savings.
However, the costs of special education could be underestimated, as the 70 points
threshold is not a hard guideline for children receiving special education. Children
treated with radiation therapy for brain tumors have a high likelihood of requiring
special education. A 10-year follow-up study of patients treated for medulloblastoma
found that 80% of the cohort received special education. [93] The data from the MGH
follow-up of proton pediatric patient shows that about 50% of the cohort received
special education.[94] Since LGGs are benign tumors, the tumor and treatment are
usually not as aggressive as some of the others CNS tumors. Hence it is expected that
the student need for special education in patients treated for LGGs should be less
than found in the MGH study (which included all types of tumors) and the Hirsch-
Hopper et al childhood medulloblastoma study. However, more studies are needed to
determine the extent to which LGG pediatric patients receive special education.
6.3 Endocrine Dysfunctions, Hearing Loss, and Sec-
ondary Cancer
There was a lower incidence of GHD, hypothyroidism, hearing loss, and secondary
cancer from proton therapy compared to IMRT. However, the reduced incidence of
those long-term health effects was not the main factor in making proton therapy
cost-effective. This result is in part due to the relative low cost associated with those
health effects compared to the cost of IQ loss and in another due to limitations of the
model.
Hypothyroidism was the second most common long-term health effect; this oc-
curred in -55% of all IMRT patients and -33% of all proton therapy patients. The
thyroid dysfunction can lead to a number of subsequent health effects, such as dia-
betes and cardiac disease. However, the cost difference from hypothyroidism between
proton therapy and IMRT was less than $1,000/patient in both the P1 and P2 case.
The costs of hypothyroidism from this model do not translate well into the full costs
of the disease as the cost from complications that could occur if hypothyroidism was
not treated (such as diabetes) was not included. Furthermore, hypothyroidism is a
condition that afflicts a patient throughout their whole life, affecting their quality of
life in ways that cannot be quantified monetarily.
GHD was the third most common long-term health effect, with -43% of all IMRT
patients and -32% of all proton therapy patients needing growth hormone replace-
ment. The costs savings from GHD were the second highest after IQ loss savings.
The cost savings associated with GHD from proton therapy was $12,000/patient for
both P1 and P2. The similarity in costs between the two cases reflected the model
design, assigning a set probability of acquiring GHD at 35% for proton therapy and
48% for IMRT. The sensitivity analysis showed that the cost of GHD had a significant
influence on the overall cost-effectiveness of proton therapy. Since the cost of GHD
occurs early after treatment, the cost is not as discounted when compared to lifetime
costs incurred from IQ loss and hypothyroidism. Since the yearly costs of growth
hormone treatment are high (ranging from $5,000-$30,000), the higher cost of GHD
means that any reduction in the incidence of GHD from proton therapy will results
in a higher cost difference.
Growth hormone therapy is usually stopped after children reach their final height.
However, some childhood cancer survivors remain growth hormone deficient into
adulthood. Gleeson et al studied a group of 74 childhood cancer survivors treated
with radiation therapy to determine the incidence of GHD at their final height. The
study found that 64% of the survivors who were treated with growth hormone as chil-
dren again tested positive for GHD.[57] The cost of GHD would be higher if treatment
into adulthood was included. However, the majority of the costs would still come from
childhood GHD treatment as adults only receive a 10th of the dose administered to
children.
There was no risk of hearing loss based on all treatment plans except for P2's
IMRT treatment plan. The dose to the cochlea was high enough to provide a risk of
0-16% for hearing loss. This finding is not surprising based on the tumor site for P1
and P2. P1's tumor is an astrocytoma located near the central region of the brain
and away from the left and right cochleas. P2's posterior fossa tumor is closer to both
cochleas, which makes the structures more likely to receive a significant dose from
IMRT, as seen in Appendix A.
In the case when hearing loss occurred, the average lifetime cost was significant
at -$7,000/patient. However, that value reflects the cost of hearing loss mitigation
and does not indicate the true cost of hearing loss to an individual. The maximum
cost an individual can accumulate from having a hearing loss from age 5 to age 70 is
$20,000. It is possible that having a hearing disability leads to fewer job opportunities
and a certain level of income loss, which was not reflected in the model. Furthermore,
studies have shown that children and adults with hearing loss report a lower quality
of life. [95] [96] There are psychological and well-being costs associated with hearing
loss that are not accounted for in this model and could make proton therapy even
more cost effective.
The overall risk of secondary cancer was 2% with proton therapy and 3% with
IMRT. These findings are in line with the risks of secondary cancers from childhood
tumors found in literature. Researchers from St. Jude Children's Research Hospital
found a 4% risk of secondary cancer 15 years after treatment from a follow-up study
of 1,283 pediatric patients treated for CNS tumors. [66] The study found a 0.4% risk
of secondary cancer for patients with LGGs as their primary tumor. The model
presented here could have overestimated the risk of secondary cancer as the risks used
in the simulations were taken from the Winkfield et al study, which calculated the
risks of secondary cancer from treatment of adult brain tumors. A study of secondary
cancers after pediatric tumors from a population in the United Kingdom found a 25-
year secondary risk of 4.2%. The Childhood Cancer Survivor Study (CCSS) found
a 30-year secondary cancer risk of 9% for pediatric patients. [64] Though the CCSS
followed a large cohort of pediatric patients (n = 14, 361), the study involved all types
of cancers, which have various degrees of malignancy and have higher incidences of
secondary cancer than LGGs.
In the P1 and P2 simulations, the costs associated with secondary cancers were
negligible (less than $1,000). Even though the cost savings from secondary cancer
is low for proton therapy, the importance of the reduction of secondary cancer cases
cannot be disregarded. First of all, the model might have underestimated the cost
associated with secondary cancer. The model limited risk of secondary cancers that
could occur in a patient's lifetime, stopping the risk of acquiring a secondary cancer
at 15 years after treatment, since reliable data beyond that time was not available.
Second, it was assumed that the cost of treatment only occurred that year, though it
is possible that the treatment of the secondary cancer resulted in additional long-term
health effects not accounted for in this model. There is a need for longer follow-up
studies of pediatric cancer survivors who were treated with proton therapy to evaluate
the true lifetime risk. Finally, the psychological cost of acquiring a secondary cancer is
difficult to measure, and more studies on the quality of life of patient with secondary
cancers should be performed.
Proton therapy could prove to be even more health and cost effective when com-
pared to IMRT. Each long-term health effect could result in a higher total cost than
those found in this thesis if the additional factors described in this chapter are ac-
counted for. There is a need for more studies evaluating the dose effects of radiation
on the risks of long-term health effects to determine the magnitude to which proton
therapy is more health effective than photon therapy. The costs associated with IQ
loss and GHD were found to be the main drivers of the total cost difference between
proton therapy and IMRT, and further studies should investigate the impact of those
health effects on their costs the patient and society.
Chapter 7
Conclusions
This thesis proposes a method for the comparison of long-term health effects and
costs for proton therapy and IMRT as treatment for pediatric brain tumors. The
method was applied to two pilot cases, P1 and P2. The risk of IQ loss and hearing
loss was calculated from each patients dose-volume histograms, using models that
relate radiation dose to the risk of long-term health effects. [42] [44] A review of
the literature was performed to determine the health risks of GHD, hypothyroidism,
and secondary cancers and the costs associated with the long-term health effects. A
Markov simulation model was developed the estimate the health and cost effectiveness
of proton therapy based on those risks.
The analysis of the treatment plans showed that there was not a large difference
in IQ loss and hearing loss between proton therapy and IMRT for the two patients
in the pilot study. However, the treatment plans are influenced by the location
and size of the tumor as well as the field arrangements. It is possible that more
significant differences between the proton therapy and IMRT dose-volume histograms
could be observed using other patients data, which would result in higher differences
in IQ loss and hearing loss. There a higher difference in the incidence of GHD and
hypothyroidism. In the model simulations, the use of IMRT treatment resulted in a
higher number of patients with health complications, with the number of additional
cases per 100 patients at 11 and 23 for GHD and hypothyroidism. Two additional
patient treatment plans (P3 and P4) were analyzed to investigate the unexpected
small difference in IQ loss between the two treatment modalities found using P1 and
P2's treatment plans. The difference in IQ loss between proton therapy and IMRT
was only 1 IQ point for both patients.
When the Markov simulations were run based on P1 and P2s health risks, proton
therapy was more cost effective due to the difference in costs associated with IQ
loss and GHD. IQ loss and GHD were also the main contributors to total costs
accumulated by the patients in the simulations. The cost difference associated with
IQ loss was equal to about $14,000/IQ point per patient for their entire life. Since the
cost associated with IQ loss is the driver of high total cost and high cost difference
between proton therapy and IMRT, this finding suggests that treatment cases where
proton therapy leads to a lower degree of IQ loss would make proton therapy more
cost-effective. Further studies should evaluate the impact of proton therapy on IQ
loss in more details.
The total costs associated with GHD were sensitive to the cost of growth hormone
treatment. Since growth hormone is expensive and children require a high dose, the
yearly cost of growth hormone therapy ranges from $5,000 to greater than $30,000.
When the Markov model is run with higher yearly costs of growth hormone treatment,
the difference in costs due to GHD was $40,000/patient for the P1 and P2 simulations.
As the dose of growth hormone required depends on the patients weight, heavier
children will incur higher costs. Long-term childhood cancer survivors tend to have
a higher relative weight compared to their peers without cancer and would be faced
with higher growth hormone costs.
If the cost savings due to IQ loss are not considered, since that cost represents un-
realized earning potential as opposed to paying for treatment, proton therapy is more
expensive than IMRT by $12,000/patient in the P1 simulation and $5,000/patient in
the P2 simulation. However, this result does not mean that proton therapy should not
be used as a treatment for pediatric brain tumors. Though hypothyroidism, hearing
loss, and secondary cancers were not associated with a high cost difference between
the two treatment modalities, the reduction in the incidence of each health-effect
provides a strong case for the use of proton therapy for the treatment of pediatric
brain tumors. Furthermore, the cost results may not reflect the total cost incurred
from long-term health effects:
1. There are additional costs associated with each of the long-term health effects
that are not reflected in this model (for example, the cost of cardiac disease
from thyroid hormone deficiency). The inclusion of those costs in future work
could indicate an even higher degree of cost-effectiveness using proton therapy,
even in the case if proton therapy is not as health effective, as presented in this
thesis.
2. The burden of long-term health effects materialize in ways that monetary costs
alone cannot represent.
This thesis provides the framework and computational tools for further analysis.
Stakeholders should not use the results from the limited simulations based on P1
and P2s health risks to make the decision about using proton therapy over IMRT (or
vice-versa). Rather, they should use the method described in this thesis to further
investigate the long-term health effects and costs of both treatment modalities. Future
work should apply the analysis method of this thesis to more patient treatment plans.
As treatment plans vary from one patient to another, this future work can help
determine the extent to which proton therapy and IMRT treatment plans differ in
practice and whether this difference provides a lower risk of long-term health effects
by using proton therapy. The estimated risk parameters should then be used in the
Markov model to determine whether proton therapy or IMRT is more effective in the
treatment of pediatric brain tumors and other solid cancers.
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Appendix A
Patient Treatment Data
Appendix A provides additional images and DVHs from each of the patient treatment
plans. The images are pictures of the P1 and P2 treatment plans in XiO@, in the axial,
sagittal, and coronal views. The GTV is contoured in red. The other lines represent
the isodose lines. DVHs of the whole brain, supratentorial brain, left cochlea, and
right cochlea are shown for P1, P2, P3, and P4.
(a) Proton therapy - axial view
(c) Proton therapy - coronal view (d) IMRT - coronal view
(e) Proton therapy - sagittal view (f) IMRT - sagittal view
Figure A-1: Proton therapy and IMRT treatment plans for P1, as seen from the axial,
sagittal, and coronal views. The red contour line delineates the GTV.
(b) IMRT - axial view
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Figure A-2: P1 DVHs of the brain and supratentorial brain from proton therapy and
IMRT treatment plans
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Figure A-3: P1 DVHs of the left and right cochleas from proton therapy and IMRT
treatment plans
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Figure A-4: Proton therapy and IMRT treatment plans for P2, as seen from the axial,
sagittal, and coronal views. The red contour line delineates the GTV.
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Figure A-5: P2 DVHs of the brain and supratentorial brain from proton therapy and
IMRT treatment plans
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Figure A-6: P2 DVHs of the left and right cochleas from proton therapy and IMRT
treatment plans
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Figure A-7: P3 DVHs of the brain and supratentorial brain from proton therapy and
IMRT treatment plans
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Figure A-8: P4 DVHs of the brain and supratentorial brain from proton therapy and
IMRT treatment plans
Appendix B
Risk and Cost Tables
Appendix B contains the detailed risk and cost tables used in the Markov model.
The risks and costs where determined based on age, gender, and/or cycle period.
The cycle period was used to assign risks and costs for events that depended on time
after treatment as opposed to age of the patient.
Probability of event and rate of event were related by the equations:
p(t) = 1 - e-" (B.1)
and
r(t) = [ln(1 - p(t))]/It (B.2)
where p(t) is the probability at time t, r is the rate at which the event occurs (number
of events per population-time), and t is time during which the event can occur.
Table B.1: Yearly probability of Normal Death based on 2006 US Life Charts
Age Male Female Age Male Female Age Male Female
1 0.000460 0.000427 34 0.001589 0.000829 67 0.019974 0.012855
2 0.000322 0.000276 35 0.001653 0.000893 68 0.021630 0.014010
3 0.000245 0.000185 36 0.001737 0.000967 69 0.023559 0.015359
4 0.000195 0.000162 37 0.001851 0.001057 70 0.025737 0.016895
5 0.000186 0.000149 38 0.002001 0.001166 71 0.028223 0.018652
6 0.000176 0.000134 39 0.002183 0.001293 72 0.031103 0.020679
7 0.000163 0.000123 40 0.002381 0.001425 73 0.034372 0.022999
8 0.000139 0.000111 41 0.002592 0.001563 74 0.037995 0.025637
9 0.000107 0.000099 42 0.002827 0.001713 75 0.042023 0.028641
10 0.000081 0.000091 43 0.003087 0.001877 76 0.046338 0.031894
11 0.000083 0.000093 44 0.003369 0.002052 77 0.051072 0.035502
12 0.000136 0.000113 45 0.003662 0.002236 78 0.056262 0.039502
13 0.000254 0.000155 46 0.003970 0.002425 79 0.061944 0.043932
14 0.000418 0.000211 47 0.004309 0.002617 80 0.068159 0.048833
15 0.000594 0.000275 48 0.004694 0.002812 81 0.074947 0.054251
16 0.000759 0.000334 49 0.005125 0.003020 82 0.082352 0.060231
17 0.000918 0.000382 50 0.005602 0.003247 83 0.090417 0.066824
18 0.001063 0.000414 51 0.006107 0.003497 84 0.099186 0.074082
19 0.001193 0.000434 52 0.006617 0.003773 85 0.108704 0.082058
20 0.001329 0.000453 53 0.007104 0.004070 86 0.119015 0.090810
21 0.001456 0.000475 54 0.007570 0.004383 87 0.130161 0.100392
22 0.001536 0.000494 55 0.008042 0.004710 88 0.142182 0.110863
23 0.001554 0.000508 56 0.008550 0.005061 89 0.155116 0.122277
24 0.001526 0.000519 57 0.009114 0.005457 90 0.168995 0.134688
25 0.001480 0.000532 58 0.009781 0.005928 91 0.183844 0.148146
26 0.001443 0.000546 59 0.010582 0.006494 92 0.199686 0.162697
27 0.001416 0.000562 60 0.011543 0.007183 93 0.216530 0.178377
28 0.001408 0.000580 61 0.012632 0.007966 94 0.234379 0.195216
29 0.001418 0.000604 62 0.013798 0.008781 95 0.253223 0.213232
30 0.001437 0.000634 63 0.014946 0.009551 96 0.273043 0.232430
31 0.001460 0.000671 64 0.016067 0.010282 97 0.293803 0.252802
32 0.001500 0.000718 65 0.017272 0.011073 98 0.315457 0.274321
33 0.001535 0.000769 66 0.018518 0.011885 99 0.337943 0.296944
100 1.000000 1.000000
Table B.2: Yearly probability of death due to tumor recurrence in the base case
Cycle Probability
1 0.0030
2 0.0030
3 0.0030
4 0.0030
5 0.0030
6 0.0098
7 0.0041
8 0.0041
9 0.0040
10 0.0040
11 0.0445
12 0.0074
13 0.0073
14 0.0073
15 0.0072
16 0.0072
17 0.0071
18 0.0070
19 0.0070
20 0.0069
21+ 0.0000
Table B.3: Yearly probability of death due to secondary cancer
Cycle Probability
1-14 0.0012
15-19 0.0013
20-24 0.0017
25-29 0.0023
30-34 0.0046
35+ 0.0000
Table B.4: Yearly probability of death due to tumor recurrence in the sensitivity
analysis
Cycle Value
1 0.0030
2 0.0030
3 0.0030
4 0.0030
5-9 0.0080
10-14 0.0090
15-19 0.0100
20-24 0.0110
25-29 0.0120
30-34 0.0130
35+ 0.0000
Table B.5: Yearly costs associated with IQ loss
Age Male IQ Cost Female IQ Cost
1 $0 $0
2 $0 $0
3 $0 $0
4 $0 $0
5-19 $15,000 $15,000
19-65 $878 $1,146
65+ $0 $0
Table B.6: Yearly costs associated with GHD by age based on the 50th percentile
weight of the U.S. population
Cost Male
N/A
$5,803
$6,589
$7,472
$8,437
$9,445
$10,511
$11,690
$13,046
$14,629
$16,473
$18,573
$20,861
$23,188
$25,347
$27,145
$0
Cost Female
N/A
$5,539
$6,329
$7,201
$8,155
$9,186
$10,333
$11,658
$13,208
$14,975
$16,874
$18,759
$20,459
$21,838
$22,840
$0
$0
Age
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17+
Table B.7: Yearly costs associated with GHD by age based on the 75th percentile
weight of the U.S. population
Cost Male
N/A
$6,254
$7,141
$8,156
$9,279
$10,462
$11,726
$13,145
$14,796
$16,725
$18,934
$21,370
$23,926
$26,441
$28,723
$30,611
$0
Cost Female
N/A
$5,989
$6,911
$7,935
$9,051
$10,266
$11,639
$13,248
$15,134
$17,259
$19,498
$21,659
$23,539
$24,992
$0
$0
$0
Table B.8: Yearly Risk of GHD
Cycle Proton Therapy IMRT
1 0.0422 0.0649
2 0.0404 0.0607
3 0.0387 0.0568
4 0.0371 0.0531
5 0.0355 0.0496
6 0.0340 0.0464
7 0.0326 0.0434
8 0.0312 0.0406
9 0.0299 0.0379
10 0.0286 0.0355
11+ 0.0000
Age
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17+
Table B.9: Yearly Risk of Hypothyroidism
Cycle Proton Therapy IMRT
1 0.0422 0.1077
2 0.0404 0.0961
3 0.0387 0.0857
4 0.0371 0.0765
5 0.0355 0.0683
6 0.0340 0.0609
7 0.0326 0.0544
8 0.0312 0.0485
9 0.0299 0.0433
10 0.0286 0.0386
11+
Table B.10: Yearly Risk of Secondary Cancer
Cycle Proton Therapy IMRT
1-15 0.00120 0.00184
16+ 0.00000 0.00000
100
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